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Abstract
The macroscopic metabolic phenotype of a cellular system, such as insulin
resistance, is the result of the integration of many hundreds or thousands of preceding
cellular events, which culminates in the cell's final response to a perturbation in the
environment. The data provided by DNA microarrays and multiple types of metabolic
measurements can be integrated to reconstruct the actions taken by a cellular system to
arrive at a particular metabolic response to a stimulus, elucidating the underlying
physiology. We employed this integrated approach for the characterization of hepatic
metabolism.
First, we implemented a novel method for functional genomics. The metabolic
response of hepatoma cells to the depletion and repletion of glutamine was characterized
in time course measurements of metabolic fluxes and metabolite pool sizes. DNA
microarrays characterized the expression profiles. The metabolic data were correlated
with the microarray data to identify coregulated clusters of genes. This study contributed
to our understanding of glutamine metabolism in hepatomas, and advanced the field of
functional genomics.
Next, we identified the hexosamine biosynthetic pathway (HBP) as a mechanism
for hyperglycemia-induced hepatic insulin resistance. Glycogen deposition and glucose
production data in mouse hepatocytes confirmed that HBP activity was negatively
correlated with insulin sensitivity. Metabolite profiling data confirmed that prolonged
incubation in hyperglycemic conditions raised the levels of hexosamine intermediates by
saturating upper glycolysis. Our data, along with previous work in muscle and adipose
tissue, underline the increasingly important role of the HBP in regulating insulin action
and energy homeostasis. A dysfunctional HBP may contribute to the pathophysiology of
Type 2 diabetes.
Finally, we analyzed the control structure of the glucose production bioreaction
network. We systematically perturbed the network and analyzed the effects on the
fluxes. We found that gluconeogenesis was the dominant flux, and therefore regulation
of gluconeogenesis determined the glucose production phenotype. G6Pase was identified
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as the enzyme in gluconeogenesis controlling the glucose production phenotype, whereas
PEPCK played a secondary role. Our conclusions here give insight into the physiology
underlying the regulation and dysregulation of hepatic glucose production with possible
application to the treatment of Type 2 diabetes.
Thesis Supervisor: Gregory Stephanopoulos
Title: Professor of Chemical Engineering
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I NTRPODUCTION
The macroscopic metabolic phenotype of a cellular system, such as insulin
resistance, is the result of the integration of many hundreds or thousands of preceding
cellular events, which culminates in the cell's final response to a perturbation in the
environment. In the context of mammalian systems, a cell exchanges information with
the environment through endocrine, paracrine, and autocrine signals, through which
information is transferred between organs and between organ systems. The binding of a
ligand, or hormone, to a receptor is the event that initiates a signaling cascade within the
cell. The net effect of this cascade will depend on the particular cascade. Some cascades
will activate transcription factors that control gene expression, and other cascades will
directly control enzyme activity, perhaps through phosphorylation. If the cascade affects
gene expression, the synthesis rate of mRNA will be upregulated or downregulated. In
turn, the translation of mRNA into proteins will also be affected. The proteins then carry
out the final cellular response to the original perturbation, functioning as enzymes for
metabolic reactions and regulators of metabolic enzymes. Changes in the intracellular
metabolite levels may feed back into the regulation of proteins. The data provided by
DNA microarrays and multiple types of metabolic measurements can be integrated to
reconstruct the actions taken by a cellular system to arrive at a particular metabolic
response to a stimulus, and gain a deeper understanding of the underlying physiology.
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The elucidation of sufficient metabolic information may require several tools, due
to the limitations of individual techniques. Release or incorporation of radioisotopes (3H
and 14C) from labeled substrates has been a long-used technique for measuring metabolic
flux. The advantages of this technique are that it is cheap, relatively quick, and the
analysis of the data is simple. The major disadvantage of this technique is that the
majority of reactions do not release or incorporate radioisotopes. True fluxes cannot be
calculated from the data due to the unknown specific activity of intracellular metabolite
pools. Incorporation of stable isotopes (2H and 13C) from labeled substrates has also been
used for many decades. Detailed mathematical models of biochemistry can extract a
cornucopia of flux data from the isotopomer labeling patterns of metabolic intermediates.
The inert nature of stable isotopes allows them to be used in human studies. And finally,
as mentioned above, the actual metabolite levels themselves may contain information
about the metabolism. Biochemical methods of measuring metabolites or GC/MS
methods of metabolite profiling are useful in this regard.
We employed this integrated approach for the characterization of hepatic
metabolism. In the functional genomics portion, metabolic data were combined with
DNA microarray data to examine gene function. In the bioreaction network analysis
portion, biochemical metabolite measurements were combined with stable isotope flux
data to create true intracellular flux maps.
1.1 Motivation
The thesis work consisted of three parts: a study in functional genomics, a study
in insulin resistance pathophysiology, and a study in bioreaction network control. In the
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first section, we demonstrated a novel method of functional genomics in which we
characterized the metabolic and transcriptional changes in mouse hepatoma central
carbon metabolism that occurred during glutamine depletion and repletion. In the
hepatoma studies, the motivation was two-fold. First, glutamine metabolism in mouse
hepatoma cells was not well studied, particularly with regard to the use of glutamine in
lipogenesis. Our stable isotope studies established the important role of glutamine in
hepatoma lipogenesis. Second, we felt that the use of time-course metabolic flux data in
conjunction with microarray data would represent a significant advance in functional
genomics. Such an approach would supply a powerful method to select genes from the
genome-wide pool with functions that were relevant to the flux in question with more
precision than previous methods.
The second part of the thesis dealt with the modulation of liver insulin action by
the hexosamine biosynthetic pathway. The resistance of muscle, liver, and fat to insulin
is the central pathophysiological event in the development of Type 2 diabetes. The
precise pathogenesis of insulin resistance is unknown, but it is known that multiple
genetic and environmental factors are involved. In an attempt to add to this knowledge,
we investigated the hexosamine biosynthetic pathway as a mechanism of hyperglycemia-
induced insulin resistance in the liver. A promising hypothesis states that excess flux
through the hexosamine biosynthetic pathway results in the increased glycosylation of
proteins. Some of these proteins are insulin signaling proteins and glycosylation leads to
a decrease in their activity, thus leading to insulin resistance. The effect of excess
hexosamine biosynthetic pathway activity has been thoroughly studied in muscle and
adipose tissue since the pathway's discovery in 1991 (111). The work detailed in this
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thesis complements the previous knowledge of insulin resistance pathophysiology. The
identification of the molecular pathophysiological mechanisms of insulin resistance and
Type 2 diabetes is essential for the development of novel and more effective therapies to
better treat patients with insulin resistance and Type 2 diabetes.
The third part of the thesis examined the control structure of the glucose
production network. The response of the network was tested by a series of systematic
perturbations in Preincubation glucose level, hormone administration, glycerol
availability, and hexosamine biosynthetic pathway activity. These perturbations
produced an array of data with many different glucose production phenotypes, and
analysis of that data gave us insight into the fluxes and the enzymes that most influenced
the glucose production phenotype. Since overactive hepatic glucose production is
characteristic of Type 2 diabetes, the identification of the key network control points is
essential for more effective therapies.
1.2 Thesis Objectives
The general objective of this thesis was to develop and apply metabolic assays for
the characterization of hepatocellular systems. In accomplishing this overall goal, the
following specific aims were pursued:
* Develop methods for the use of radioisotopes for the measurement of
enzymatic fluxes
* Develop methods for the measurement of metabolite levels using GC/MS
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* Characterize the metabolic and transcriptional response of Hepal-6 mouse
hepatoma cells to glutamine oscillations for the implementation of a novel
functional genomics strategy
* Develop methods for the isolation and culture of mouse hepatocytes
* Quantify the relationship between the activity of the hexosamine biosynthetic
pathway and liver insulin action
* Dissect the control structure of the glucose production flux network
1.3 Thesis Description
The thesis then describes the context for this work, methods used, the results
obtained, and the conclusions drawn from the results. The thesis is organized into 7
chapters:
* Chapter 1: The motivation behind the present work is presented. The
objectives of the thesis are provided.
* Chapter 2: Literature review of functional genomics and insulin resistance is
given to the reader.
* Chapter 3: The materials and methods used in the hepatoma work and the
hepatocyte work are listed. More detailed protocols are provided in the
appendix.
* Chapter 4: The work involving the study of the response of mouse hepatoma
cells to glutamine oscillations is presented. This work explored methods to
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correlate metabolic flux data with gene expression data in order to advance the
field of functional genomics.
* Chapter 5: The work studying the role of the hexosamine biosynthetic
pathway in liver insulin action is presented. These results advanced the
understanding of the pathophysiology of hepatic insulin resistance and Type 2
diabetes.
* Chapter 6: The work studying the control structure of the glucose production
network is presented. The results advanced the understanding of the control
of hepatic glucose production with possible application to the treatment of
hyperglycemia in Type 2 diabetes.
* Chapter 7: The conclusions and the recommendations for future work are
provided.
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2 LITERATURE REVIEW
This chapter will provide the background in which our studies of functional
genomics and Type 2 diabetes took place. In the area of functional genomics, we
attempted to develop a new method that coupled flux measurements with DNA
microarray data. The context for this study will be reviewed first. We will then review
the existing knowledge base in insulin resistance and Type 2 diabetes, which set the
landscape for our hepatocyte studies.
2.1 Functionat Genomics
The explosion of genomic knowledge in the past 15 years has left us with an
abundance of genes with unknown or poorly characterized function. To understand
physiological systems, we must identify gene function and the regulatory interactions
between genes. In a study from 1998, RT-PCR measurement sets for 112 genes at
various times during rat central nervous system development (198) revealed features of
the regulatory cascade. The advent of microarrays, of course, enabled a sampling of
genome-wide expression data, and DNA microarrays have become the key experimental
tool in functional genomics. The power of expression profiling is most evident in
systematic experiments that explore a varied set of conditions. Sampling a smoothly
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varying process over time provides data redundancy, and coregulation of genes across a
set of biological conditions or across time reveals hypothetical functional gene groups.
Early studies focused on applying these principles. DeRisi et al. (44) followed
essentially all the genes in the yeast Saccharomyces cerevisiae growing in culture
through its diauxic shift. Genes with related known metabolic function showed similar
expression evolution over time. The transcriptional changes observed in other genes
helped flesh out knowledge of the metabolic pathways involved. Their study helped
demonstrate the feasibility and utility of this approach to genome-wide exploration of
gene expression patterns. Caenorhabditis elegans was profiled over a set of
developmental phases, growth conditions, and genetic mutations. The diversity of these
conditions yielded strong groupings of co-regulated genes. They visualized the data as a
gene expression map, which they used as a gene discovery tool (88). Progression of
expression during development was followed during early metamorphosis in Drosophila
(199), and genes were grouped according to their pattern of expression over the different
phases of development. Spellman et al. (174) followed the yeast S. cerevisiae through
two cell cycles, first synchronizing the cells in the culture with multiple cycle arrest and
release methods. Using periodicity and correlation algorithms, they identified 800 genes
that met an objective minimum criterion for cell cycle regulation, and functional
relationships between different phases of the cycle were suggested. Despite the visually
clear and alluring expression patterns that resulted, the detailed conclusions of this and
subsequent synchronization studies with microarrays have been called into question over
statistical issues and whether most cells are in fact synchronized (33). These early
applications of DNA microarrays illustrated the possibilities for the technology and the
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challenges in dealing with these large data sets that come with uncertain error behavior
and biology.
Increasing diversity of the conditions set, up to a point, yields stronger and more
informative groupings of genes by coregulation. The usefulness of more experiments is
determined by considering biological complexity and using algorithms to find patterns.
Despite the rigor of any mathematical algorithm, these clusters still are subject to the
caveat that similarity of response results in a "guilt by association" inference (28) and not
proof of functional relatedness. These results are merely a starting point for more
confirmatory experiments to pin down the role of a particular gene. Marcotte et al. (110)
were able to group proteins by correlated evolution, correlated messenger RNA
expression patterns and patterns of domain fusion to determine functional relationships
among the 6,217 proteins of the yeast S. cerevisiae. Comparing these predictions to
accepted functional annotations indicated fairly limited accuracy of the coregulation
based inferences, although this depends on the set of conditions over which the
expression profiles are obtained.
One study in particular stands out for its novelty. Hughes et al. (74) profiled a
large set of different single-gene disruption mutants in yeast, comparing their
transcriptional state to the wild-type strain. The resulting patterns (Fig. 2.1) provided a
visualization of major pathway groupings and provided functional inferences for
previously unannotated genes. Figure 2.1, in which rows and columns of the expression
ratio data were reordered according to agglomerative hierarchical similarity clustering,
illustrates the important distinction between two modes of functional inference.
Proximity of two genes in the horizontal dimension indicates the degree of coregulation.
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Figure 2.1. Expression responses to single-gene deletions in
yeast. Each row represents the up- (red) or downregulation
(green) of expression in response to a single-gene disruption in
yeast. Only 300 genes (columns) are shown. These were the most
responsive among the -6000 yeast genes measured in each two-
color hybridization experiment. Columns, and independently the
rows, have been rearranged via agglomerative hierarchical
clustering to place rows with similar response patterns near each
other, and columns with similar response patterns near each
other. Each red or green island then represents a coordinated
transcriptional response that is similar for each of a set of gene
disruptions.
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These genes respond similarly to the disruptions of other genes. However, this kind of
similarity often is the result of a fairly uninteresting downstream convergence of
pathways, such as a global stress signature. Proximity on the vertical axis means two
disrupted genes produced similar cell responses at the gene expression level, which was a
stronger indication of functional similarity. The utility of this approach was validated by
examining profiles caused by deletions of uncharacterized genes. They identified and
experimentally confirmed that eight uncharacterized open reading frames encoded
proteins required for sterol metabolism, cell wall function, mitochondrial respiration, or
protein synthesis. (74). This approach was extended even further to characterize
pharmacological perturbations by the identifying the target of a drug compound. The
expression pattern of a knockout mutant that matched the pattern of the drug revealed the
drug's probable target.
This leads to a second class of functional genomics experiments that uses
microarray expression data as the signature of a perturbation. Genes that are
differentially expressed when the system is exposed to a perturbation such as a toxin
become indicators of an inflamed state. In this case, we are not so interested in the
functions of these differentially expressed genes as we are in how their expression pattern
can uniquely describe the toxin. As examples, toxicity patterns in rat liver were produced
by profiling the response to compounds of known toxicity (118, 194). The expression
profiles produced by compounds under study then can be interpreted for the mechanism
and likelihood of toxicity. Biological interpretation of the responding genes also gives
clues to the mechanisms of toxicity. Similarly, efficacy landmarks can be provided by
profiling drugs with known mechanisms of action. Expression responses to psychoactive
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compounds in primary human neurons in vitro were used to develop classifiers for
antidepressant, antipsychotic, and opioid drug action (63). The products of such projects
can be thought of either as biomarkers for particular classification decisions or as a
general resource for interpreting the bioactivity of new compounds.
Finally, one of the most common experiment types in the drug discovery and
diagnostics arena is the search for biomarkers of a particular human phenotypic end
point. Cancer outcome prognosis is a very popular category because genetic variation is
critical to cancer phenotype. Alizadeh et al. (4) found expression patterns indicative of
survival in B-cell lymphoma patients and characteristics of two subtypes of large diffuse
lymphoma B cells. In this study, the microarray probes were chosen to target genes
expressed in lymphoid cells and to be relevant to immune response. A subset of the
predictive markers was confirmed in follow-up validation studies with PCR. Van t' Veer
et al. (188) used DNA microarray analysis on primary breast tumors of 117 young
patients. After applying supervised classification, they were able to find an arithmetic
function of the expression levels of 70 transcripts that predicted metastasis of breast
tumors out of -25,000 profiled. This predictor was validated in a larger follow-up study
of almost 300 patients (189). However, the use of a supervised classification, as opposed
to an unsupervised method such as principal component analysis, was a weakness of that
study. A recent meta-analysis of 84 microarray-based cancer outcome studies found that
very few of them accomplished thorough validation and that, not surprisingly, larger
cohorts and larger probe sets increased the chances of finding good biomarkers (131).
There is a close relationship in these studies between developing predictors and
recognizing subphenotypes of disease. In general, the detailed molecular phenotype
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provided by expression profiling allows discrimination between multiple states that may
at one moment have the same gross phenotype (lymph node status or histological grade)
but for which the subsequent progression of events differs.
2.2 Insulin Resistance and Type 2 Diabetes
In the past few decades, diabetes mellitus has pushed its way to the forefront of
public health consciousness. In conjunction with the spread of obesity, Type 2 diabetes
mellitus has reached epidemic proportions in many developed countries, most notably in
the United States. As of 2004, there were an estimated 16 million people with Type 2
diabetes in the US (33% were undiagnosed) and approximately 1.3 million more are
newly diagnosed each year. As of 2002, Type 2 diabetes was the 6th leading cause of
death in the United States. This disease is caused by multiple genetic factors, but diet and
lifestyle are also factors. The etiology of this complex disease has not been unraveled,
but its symptoms and the various organs and molecules involved in glucose homeostasis
have been described since ancient times (89, 148).
2.2.1 Historical Review of Diabetes
In 1500 B.C., the Papyrus Ebers of Ancient Egyptians had a number of remedies
for combating the passing of too much urine (polyuria). Hindus in the Ayur Veda
recorded that insects and flies were attracted to the urine of some people, that the urine
tasted sweet, and that this was associated with certain diseases. Between that time and
the 19 th century, many physicians and scientists such as Arataeus of Cappadocia ( t
century A.D.), Celsus (1st century A.D.), Chen Chuan of China (7t h century A.D.)
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Thomas Willis of Oxford (17th century A.D.), and Avicenna the Arab (11 th century A.D.),
noted the symptoms of excessive urination and sweetness of urine.
Attempts at treatment began when no more was known of diabetes than the
polyuria. John Rollo, Surgeon-General to the Royal Artillery, treated Captain Meredith
in 1796 by dietary restriction with considerable success. The patient survived for at least
a year. Rollo also noticed the smell of acetone on the breath of diabetics, presumably
those in the advanced stage of Type 1 diabetes. Around the same time, Thomas Cawley
made the observation that the pancreas of a patient who had died of diabetes showed
stones and tissue damage. The significance of this was not apparent until Minkowski's
work 101 years later.
In 1889, Mehring and Minkowski produced diabetes mellitus in dogs by removing
the pancreas. The results were glycosuria, polyuria, intense thirst, ravenous hunger, and
loss of weight despite normal food intake. Glycogen disappeared from the liver and
skeletal muscle. These results were unexpected because the prevailing view at the time
was that the pancreas only produced digestive enzymes. The removal of the pancreas had
been for an experiment exploring the role of the pancreas in digestion. But once
Minkowski saw the results of the pancreatectomy, he realized immediately what they
meant and tested the urine for glucose. With these results, he knew that the pancreas
produced some antidiabetic substance, but he could not purify it. In 1921, Banting and
Best successfully extracted insulin from the pancreas. The news of this discovery spread
quickly throughout the world and brought hope to sufferers of Type 1 diabetes mellitus.
It soon became apparent that there were two types of diabetes mellitus - insulin
dependent, and non-insulin dependent. Physicians had long appreciated the clinical
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distinction, but they did not know that the two types of diabetes were caused by different
pathogenic mechanisms. In 1936, Harold Himsworth demonstrated insulin sensitivity in
Type 1 and insulin resistance in Type 2 diabetes.
Forms of oral treatment for Type 2 diabetes have been used since the 1930's, but
none were really effective. In 1942, M.J. Janbon, a professor at Montpellier, France,
discovered that a substance in the class of sulphonylureas could induce the fall of blood
glucose. They were able to infer that sulphonylureas stimulated the secretion of insulin,
although this did not fully explain their mode of action. G. Unger first described the use
of biguanides for Type 2 diabetes therapy in 1957 (186). Metformin (dimethylgibuanide)
reduced hepatic glucose output as its mode of action, but did not receive FDA approval
for Type 2 diabetes until 1994.
2.2.2 Pathogenesis of Type 2 Diabetes
Diabetes mellitus is the most common endocrine disorder, currently affecting over
170 million people worldwide (202). More than 90% of the patients are of the Type 2
diabetes variety. The major pathophysiological event contributing to the development of
Type 2 diabetes mellitus is resistance of target tissues to insulin (Fig. 2.2). Insulin
stimulates glucose uptake in mainly skeletal muscle and fat, and inhibits the glucose
production from the liver. In a pre-diabetic insulin resistant state, these organs do not
respond properly to insulin, leading to hyperglycemia. The pancreas can partially
compensate for this by increasing its output of insulin, but fasting glucose will remain
mildly high. This increased secretory load on the pancreas, combined with glucose
toxicity, will result in progressive beta cell dysfunction. Eventually, complete beta cell
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Figure 2.2. Pathogenesis of Type 2 diabetes. Genetic and
environmental influences converge to cause insulin resistance.
Compensatory n-cell hyperplasia can maintain
normoglycemia, but eventually, [3-cell secretory dysfunction
sets in, leading to impaired glucose tolerance and eventually
frank diabetes.
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failure occurs and Type 2 diabetes will manifest itself in uncontrolled plasma glucose
levels.
The development arc of Type 2 diabetes is a process that takes many years, and
the precise sequence of pathophysiological events is unknown. However, recent
advances have contributed to our understanding of the underlying molecular mechanisms
of insulin resistance. Investigators have attacked the problem with
* Biochemical in vitro studies
* Gene targeting in mice
* Analysis of natural mutations in insulin resistant mice
* Analysis of natural mutations in insulin resistant human patients.
The development of novel effective therapies for Type 2 diabetes depends on the
advancement of our understanding of the disease. The following sections in this chapter
will concentrate on the existing knowledge of hepatic insulin resistance. The
contributions of other tissues such as the pancreas, skeletal muscle, and adipose tissues to
insulin resistance are outside the scope of this project, as we are working with isolated
cultured hepatocytes.
2.2.3 The Insutin Signating Pathway
The insulin signaling pathway (Fig. 2.3) is mostly conserved across the insulin
sensitive tissues. The insulin receptor consists of extracellular ligand binding and
intracellular tyrosine kinase domains. When insulin binds the extracellular portion of the
receptor, the kinase is activated and the receptor autophosphorylates specific intracellular
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Figure 2.3. Insulin signaling and deactivation pathways across adipose,
muscle, and liver tissue. Insulin signaling involves binding of insulin to its
receptor followed by a cascade of intracellular events, depicted as activation
pathways. Negative modulation of insulin action can be mediated via various
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dependent kinase.
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tyrosine residues. This recruits a number of scaffolding proteins: insulin receptor
substrate (IRS) proteins, casitas B-lineage lymphoma (Cbl), or Cbl associated protein
(CAP). These proteins themselves then become phosphorylated (14, 27, 101, 130, 139).
IRS proteins are not catalytic themselves, but harbor several interaction domains to
recruit other signaling molecules like phospho-inositide-3-kinase (PI3-kinase) to form
large protein complexes at the plasma membrane. There are multiple IRS proteins, but
the most important ones in the regulation of carbohydrate metabolism appear to be IRS- 1
and IRS-2 (200). Knockouts of IRS-2 in mice show insulin resistance in muscle, fat, and
liver, and develop overt diabetes as a result of P-cell failure (146). In mice, disruption of
the IRS- 1 gene results only in insulin resistance of muscle and fat (205). Rare mutations
of the IRS- 1 protein found in humans are associated with insulin resistance (201). There
are also data showing that IRS dysfunction in muscle may be a result of adipocyte action.
For example, circulating free fatty acids (FFA) and the adipokine tumor necrosis factor a
(TNFa) may increase serine phosphorylation of IRS proteins, disrupting insulin
signaling (200). Finally, prolonged excess stimulation with insulin (hyperinsulinemia)
may result in regulated degradation of IRS protein (160).
Downstream of the IRS proteins, the PI 3-kinase is a central mediator of insulin
signaling. PI 3-kinase isoforms can be divided into three classes, but only Class Ia PI 3-
kinases participate in insulin signaling. Binding of PI 3-kinase to phosphorylated site on
IRS proteins leads to activation of PI 3-kinase. PI 3-kinase generates of phosphatidyl-
inositol-3,4-bisphosphate (PIP2) and phosphatidyl-inositol-3,4,5-trisphosphate (PIP3),
which bind to the phosphoinositide-dependent kinase 1 (PDK1). Therefore, these two
phospholipids may attract PDK1 and the putative PDK2 to the plasma membrane.
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Known substrates of the PDKs are the protein kinase B (PKB) and also atypical forms of
protein kinase C (PKC) (93).
PKB (also called Akt) is a serine/threonine kinase with high homology to PKA
and PKC. So far, three different isoforms of PKB have been identified in mammals (a,
[5, y). PKB is conserved from invertebrates to mammals and shows high homology
among different species emphasizing its pivotal role in development, cell proliferation,
and metabolism (190). PKB mediates effects of insulin on glucose transport, glycogen
synthesis, protein synthesis, lipogenesis, and suppression of hepatic gluconeogenesis.
PKB regulates both glucose uptake via facilitated glucose transporters (GLUT family)
and intracellular glucose metabolism in insulin sensitive tissues, such as skeletal muscle
(3). Under non-stimulated conditions, PKB is located in the cytoplasm and stimulation
with insulin results in translocation of PKB to the plasma membrane, where it may bind
to PIP2 and PIP3 (90, 190). At the plasma membrane, PKB co-localizes with PDK and
becomes activated by phosphorylation of its two principal regulatory sites, Thr308 and
Ser473. Phosphorylation of both sites is essential for the activation of PKB. PDK1 is the
kinase phosphorylating Thr308, while the mechanism of phosphorylation of the Ser473
residue remains controversial and the corresponding kinase PDK2 still needs to be
identified (69). Following activation, PKB detaches from the plasma membrane to affect
metabolic processes such as glycogen synthesis and glucose transport. Parts of the
activated PKB also translocate through the cytoplasm into the nucleus by an unknown
mechanism to affect gene expression (5, 119, 190). Substrates for a direct
phosphorylation by PKB include glycogen synthase kinase-3 (GSK-3) and members of
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the Foxo-family of transcription factors, which are critically involved in the insulin-
dependent regulation of glucose homeostasis.
Termination of the insulin signal is critical for the maintenance of metabolic
control. Signaling of the insulin receptor cascade is terminated by specific phosphatases.
One of the key phosphatases in this context is the protein-tyrosine-phosphatase 1 B
(PTP IB). Mice lacking the PTP lB gene exhibit increased insulin sensitivity and fail to
develop insulin resistance under a high-fat diet (48). In addition, the inhibition of PTP1B
activity by systemic application of antisense oligonucleotides specific for PTP 1B
improved insulin sensitivity and glycemic control in diabetic mice (216). Other
phosphatases relevant for the termination of insulin signaling include phosphatase and
tensin homologue (PTEN), which inactivates the lipid products of the PI 3-kinase and
also SH2-containing 5'-inositol-phosphatase (SHIP2). Knockout mice with a
homozygous deletion of the SHIP2 gene display increased insulin sensitivity and
hypoglycemia because of an inhibition of hepatic glucose production (29). Also,
antisense oligonucleotides specific for PTEN drastically improved glycemic control in
diabetic ob/ob and db/db mice (26). Therefore, PTP1B, SHIP2, and PTEN can be
regarded as potential therapeutic targets for the treatment of Type 2 diabetes.
2.2.4 Hepatic Glucose Production
The fasting hyperglycemia in patients with Type 2 diabetes is the clinical
correlate of the increased glucose production by the liver caused by insulin resistance.
Hepatic glucose production is the sum of gluconeogenesis and glycogenolysis, and
insulin and glucagon have opposite regulatory effects on key enzymes in both pathways
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Figure 2.4. Regulatory actions of insulin and glucagon on central carbon
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(Fig. 2.4). Insulin activates glucokinase at the transcriptional level, and glucagon, when
present, exerts a dominant repressive effect on glucokinase transcription (79). Insulin
suppresses the expression of key gluconeogenic enzymes phosphoenolpyruvate
carboxykinase (PEPCK) and the glucose-6-phosphatase catalytic subunit (G6Pase) (12),
opposing the effect of glucagon. Insulin also inhibits pyruvate carboxylase (PC)
expression, whereas glucagon activates the PC protein (80) and increases flux through PC
(2). Glucagon converts pyruvate kinase (PK) to a lower activity form, and insulin is able
to convert PK back to a high activity form (17). Insulin also increases expression of PK
and lengthens the half-life of the mRNA, while glucagon has the opposite effect for both
of these mechanisms in isolated hepatocytes (39) and intact rats (191). Glucagon
activates glycogen phosphorylase through cAMP production, and insulin antagonizes this
through phosphodiesterase-catalyzed destruction of cAMP (78). By the same cAMP
mechanism, glucagon also phosphorylates and inhibits glycogen synthase activity (51). It
is mentioned in the next section that insulin activates glycogen synthase through PP1,
which opposes glycogenolysis.
There is a consensus that hepatic glucose overproduction is the result of
dysregulation of the two key gluconeogenic enzymes, PEPCK and G6Pase (13, 156, 184,
187). Insulin inhibits the expression of both of these enzymes at the transcriptional level
(12) and it is widely accepted that this process is mediated by activation of PKB (100,
163). The promoters of both the PEPCK and G6Pase genes contain so called insulin-
responsive elements (IREs) that are essential for the effect of insulin on the regulation of
those genes. Data from in vitro studies have shown that three Foxo-family transcription
factors (Foxo a, Foxo3a, and Foxo4) are capable of binding to these structures (65, 163,
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207) and that phosphorylation of Foxo-proteins by PKB results in transcriptional
inactivation, nuclear export, and consequently inhibition of target gene expression (65,
204). There is increasing evidence that Foxo-proteins are critically involved in the
insulin-dependent regulation of gluconeogenic gene expression and insulin resistance in
vivo. For example, the partial knockout of the Foxol gene in insulin resistant mice
resulted in reduced G6Pase mRNA and insulin levels comparable with metabolically
unaffected control animals (128). Furthermore, transgenic animals with liver and
pancreatic P-cell specific expression of a constitutively active, non-insulin-regulatable
Foxol point mutant (Ser253Ala) have a diabetic phenotype (127, 214). Therefore, these
results demonstrate a causal relationship between Foxol regulation by insulin and
glycemic control in vivo. In addition, the PPARy co-activator- 1 (PGC- 1), a factor
integrating the effects of glucocorticoids and cAMP on gluconeogenic gene expression in
the liver (68, 192, 211) is also regulated by PKB and Foxol (147), therefore providing
additional evidence that PKB and Foxo 1 are critical parts of the network integrating
hepatic glucose production.
In addition to the Foxo transcription factors, members of the hepatocyte nuclear
factor (HNF) family of transcription factors may be involved in the regulation of glucose
metabolism by insulin. For example, HNF 1 enhances the effect of insulin on the
promoter of the G6Pase gene via interaction with an IRE (177). In addition, consensus
sequences for HNF3 and HNF4 have been identified in the G6Pase promoter, although
the functional implications with respect to the regulation of the promoter by insulin are
unclear (206). As an aside, the HNF3 family of proteins has been renamed as the Foxa
family. HNF3a, HNF3P3, and HNF3y have been renamed Foxal, Foxa2, and Foxa3,
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respectively (82). Knockout mice homozygous for a null mutation of HNF3 display a
phenotype with a complex impairment of glucose metabolism including persistent
hypoglycemia (83). Recently, there is increasing evidence for an involvement of HNF4
in the insulin-dependent regulation of hepatic gene expression. For example, HNF4 is
involved in the PI 3-kinase/PKB-dependent stimulation of glucokinase gene expression
by insulin, an important mechanism to increase glycolysis (159). On the molecular level,
HNF4 may directly interact with Foxol 1, and Foxol may act as an inhibitor of HNF4. In
this setting, insulin stimulates HNF4 transcriptional activity by sequestering Foxo 1 from
HNF4 (70). However, although genetic defects of some HNF transcription factors (e.g.,
HNF I cc, HNF4x) are the basis for some forms of maturity-onset diabetes of the young
(MODY), the role of HNF transcription factors in the pathogenesis of Type 2 diabetes
remains unclear.
2.2.5 Hepatic Gtycogen Synthesis
Glycogen synthase, the rate-limiting enzyme in glycogen synthesis, is regulated
through a complex cascade of protein kinases and phosphatases. The activity of glycogen
synthase is determined by the phosphorylation state of the enzyme and is under hormonal
control (30). The enzyme can be phosphorylated at multiple sites by more than 10
protein kinases (153) that in general inhibit enzyme activity (54). Insulin activates
glycogen synthase by stimulating its dephosphorylation (43, 97, 98). An insulin-
stimulated protein kinase has been shown in vitro to phosphorylate and activate PP1 G
(43), the glycogen-bound form of type-1 protein phosphatase. Glucosamine
downregulates basal PP 1 activity with greater potency than glucose, and both
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glucosamine and high glucose significantly reduce insulin's ability to stimulate PP1 (35).
Glycogen synthase activity may also be regulated by the addition of a single GlcNAc
monosaccharide on serine/threonine residues (136, 137). Insulin also antagonizes the
activation of glycogen phosphorylase through destruction of cAMP (78). Glycogen
phosphorylase is not activated in the absence of glucagon, but the presence of insulin
may keep the basal activity to a minimum.
Currently, probably the best-characterized substrate of PKB is the GSK-3, a
critical enzyme regulating glycogen synthesis. There is abundant evidence that PKB-
mediated inhibition of GSK-3 is the key mechanism through which insulin promotes
glycogen synthesis. The major part of glucose taken up from the blood after insulin
stimulation is stored as glycogen in skeletal muscle. Dysregulated glycogen synthesis is
a critical feature in diabetes mellitus as glycogen synthesis rates in diabetic patients are
approximately 50% lower than in healthy subjects (167). Under basal conditions, GSK-3
is constitutively active and phosphorylation of glycogen synthase by GSK-3 inhibits
glycogen synthesis. The phosphorylation of GSK-3 by PKB results in inhibition of this
kinase. Furthermore, expression of a GSK-3 mutant that is insensitive to phosphorylation
by PKB results in a reduction of insulin-mediated glycogen synthesis (179).
Impaired hepatic glycogen storage and glycogen synthase activity is a common
finding in insulin resistance (19, 37) and polymorphisms in the glycogen synthase gene
have been described in insulin resistant patients. The most frequent mutations are the so-
called XbaI mutations and Met416Val within intron 14 and exon 10, respectively.
Currently, there are conflicting data on the correlation of these polymorphisms with
insulin resistance and Type 2 diabetes mellitus (7, 62, 81, 152, 176).
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2.2.6 Mutations Associated with Insulin Resistance
Although there is little doubt about the existence of a genetic component in Type
2 diabetes, the heterogeneity of the disease is a confounding factor for the interpretation
of genetic studies. In general, two methods have been used for the study of genetic
factors: the candidate gene approach and the genome-wide scan approach. The candidate
gene approach examines genes with a rational role in the disease. The statistical
association of a given allele and a phenotype (insulin resistance) is tested in unrelated
individuals. The genome-wide scan or linkage approach locates genes through their
genomic position. Family members sharing a specific phenotype will also share genetic
markers surrounding the gene(s) involved.
Mutations found in candidate genes are listed first in Table 2.1, and relatively few
mutations have strong evidence supporting the association thus far. A naturally occurring
Alal 134Thr mutation in the insulin receptor resulted in markedly deficient insulin-
stimulated phosphorylation (124). An Argl 174Gln mutation was discovered in the
intracellular receptor -subunit (123). A Met614Val mutation in IRS- was associated
with insulin resistance (201). The Gly972Arg polymorphism in IRS-1 may have a weak
association with Type 2 diabetes (134), although possibly through ,-cell dysfunction
rather than insulin resistance (141, 178). A Met326Ile mutation in PI3-K has some data
in support of its association with insulin resistance, but the data are not currently
definitive (15, 66). PKB/Akt was found to have a dominant negative missense mutation
within the kinase domain (55).
Several different mutations have been described for glycogen synthase (7, 62, 81,
152, 176), but the associations with insulin resistance remain controversial. The most
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Table 2.1. Mutations in molecules that are reported to be associated with
insulin resistance in humans.
Molecule Nature of the Mutation Mechanism Reference
IR Alal 134Thr Insulin signaling disruption 124
Arg 174Gln ( subunit) 123
IRS-1 Met614Val Insulin signaling disruption 201
Gly972Arg 134, 141,
178
PI3-K Met326Ile Insulin signaling disruption 15, 66
PKB/Akt Arg274His Insulin signaling disruption 55
GS Met416Val, Gln7I1His, Altered glycogen storage 7, 62, 81,
Xba-mutation; 152, 176
PPARG Pro l2Ala Insulin resistance 102, 134
INS Class III VNTR ,-cell dysfunction 134
KCJN11 Glu23Lys [- or a-cell dysfunction 59
ABCC8 T761 (exon 18) P-cell dysfunction 59
PPARGC-1 Ser482 Unclear, possibly pleiotropic 47
CAPN10 Intronic SNP43, G Unclear, possibly pleiotropic 73
Intronic SNP44, C 42, 50,
171,195
VNTR = variable number tandem repeat;
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robust single candidate variant is the highly prevalent Pro 12Ala polymorphism in
peroxisome proliferator-activated receptor y (PPARy) (102, 134). In this case, the alanine
genotype results in greater insulin sensitivity (40, 47, 126). The Gly483Ser
polymorphism in PGC 1 a, a transcriptional cofactor, might also be associated with Type
2 diabetes via as yet unknown mechanisms (47).
Among the many candidate genes for insulin secretory dysfunction, those
encoding Sulfonylurea receptor 1 (SURI) and Potassium-inward rectifier 6-2 (KIR6-2)
have been most extensively studied. The two genes - ABBC8 and KCNJ11, respectively
- are adjacent to one another on chromosome 11. There is insufficient evidence for
association of two widely studied SUR1 polymorphisms (exon 16-3t/c, exon 18 T759T)
with Type 2 diabetes (59). Meta-analyses on the Glu23Lys variant in the KIR62 gene
are more robust, suggesting that the risk of Type 2 diabetes increased by about 15% for
the Lys allele, probably through decreased insulin secretion (59).
Several findings from genome-wide scans have been replicated in multiple
studies, but generally, positional cloning of the causative gene has not successful. The
first diabetes gene cloned was CAPN10 on chromosome 2 (34, 73). It encodes for
calpain-10, a cysteine protease, which is ubiquitously expressed (104, 180).
Polymorphisms UCSNP-43 (73) and UCSNP-44 (42, 50, 171, 195) were found to be
associated with Type 2 diabetes. Genetic variants might affect insulin sensitivity (8),
reduced insulin secretion (175), or both (185).
A peculiar possibility is the relation of diabetes to imprinted genes, whose
expression varies depending on the sex of the transmitting parent. The class III allele of
the variable number tandem repeat near the insulin gene (chromosome 1 lpl 5) might
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relate to Type 2 diabetes (133). The class III allele is associated with decreased amount
of insulin mRNA. Only paternally transmitted class III alleles were found to be
associated with diabetes in one study (76).
2.2.7 Current Therapies for Hepatic Insulin Resistance
The final piece of the diabetes puzzle is to take the knowledge of the biology and
the pathophysiology and implement a therapeutic strategy. The major goal of Type 2
diabetes therapy is protecting patients from the long-term complications of the disease.
Interventions are initially aimed at increasing tissue insulin sensitivity because insulin
resistance plays such a fundamental role in the pathogenesis of Type 2 diabetes. Changes
in diet and exercise habits can improve insulin sensitivity, and can be combined with
drugs that further enhance insulin sensitivity. Figure 2.5 describes current therapies
available and their sites of action. Only thiazolidinediones and metformin will be
discussed below, as the scope will be limited to liver insulin resistance.
Drugs that enhance insulin sensitivity are primarily those of the
thiazolidinediones (TZDs) class, which not only reduce glycemia, but also enhance
vascular function and ameliorate the dyslipidemia and inflammatory milieu of Type 2
diabetes (210). TZDs affect liver insulin sensitivity in an indirect manner. They
primarily activate PPARy in adipose tissue and alter adipose metabolism and distribution.
The redistribution of tissue triglyceride from visceral stores reduces levels of circulating
FFA apparently by sequestration in a less lipolytic subcutaneous compartment (208).
TZDs also reduce circulating concentrations of pro-inflammatory cytokines that promote
insulin resistance (e.g., TNFa and interleukin 6) and at the same time increase
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Figure 2.5. Pharmacological treatment of hyperglycemia according
to site of action. GLPI = glucagon-like peptide 1. DPP-IV =
dipeptidyl peptidase IV.
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concentrations of adiponectin, which has insulin-sensitizing and anti-inflammatory
properties. The multiple effects of TZDs on adipose tissue metabolism and cross-talk of
these signals with liver and skeletal muscle, as well as pancreatic n-cells and the vascular
endothelium, might account for the enhancement of insulin action and improvement in
insulin secretion with these agents, as well as several beneficial effects on vascular
function (120). The action of the TZDs to redistribute visceral triglyceride can reduce
hepatic lipid content in non-alcoholic steatohepatosis, which is closely related to obesity
and insulin resistance (210).
Metformin is a highly effective antihyperglycemic drug that works independently
of the pancreas. It decreases hepatic glucose output and has been shown to have a
beneficial effect on cardiovascular outcomes (9, 36, 108). It acts through the recently
discovered mechanism of LKB phosphorylation of AMPK (166). Metformin has less
robust effects on insulin resistance, inflammatory markers, and vascular function
compared with the TZDs, but its benefit in abrogating some of the weight gain commonly
observed with insulin sensitizers and insulin secretagogues adds important value to this
drug.
A potential new class of therapeutics inhibits fructose-l1,6-bisphosphatase
(FBPase) to control gluconeogenesis in Type 2 diabetes (49). Inhibition of this enzyme,
which catalyzes the second-to-last step in gluconeogenesis, decreases gluconeogenesis
while avoiding direct effects on glycogenolysis, glycolysis, and the tricarboxylic acid
cycle. Furthermore, the near normal clinical profile of patients genetically deficient in
FBPase who manage their diet and avoid prolonged fasting (56) suggests that FBPase
inhibitors may exhibit an adequate safety margin.
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2.3 Research Opportunities
In this background, we saw opportunities to contribute to the advancement of
fields of functional genomics and Type 2 diabetes research. The correlation of metabolic
flux to gene expression patterns was a novel method to discover more meaningful
clusters of coregulated genes. The hepatoma system provided a platform that was
amenable to rapid experiments.
The study of the hexosamine biosynthetic pathway as a mechanism of liver
insulin resistance was complementary to the data in the literature for muscle and adipose
tissue. The studies in muscle and adipose tissue concentrated on the insulin sensitivity of
the glucose transporter system, and there was only a single publication examining
glycogen deposition, which was done in adipocytes (114). This landscape offered an
opportunity to break new ground not only in the liver, but also in studying the effect of
modulating the HBP activity on glycogen deposition and glucose production. Our
laboratory developed new expertise in metabolite profiling, which would allow us to
examine the intracellular effects of modulating the HBP activity in a way that was novel
to the field of hexosamine pathway study.
Finally, the intracellular flux maps allowed us to examine the control structure of
the glucose production network in unprecedented detail and gain physiological insight
into the determination of the glucose production phenotype, which is dysregulated in
Type 2 diabetes. The stable isotope flux estimation expertise contained in the software
Metran is unique to our laboratory, and allowed us to estimate the effect of systematic
perturbations to the glucose production network.
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Taken together, we felt that this work would be extremely novel and contribute
greatly to the fields of functional genomics and Type 2 diabetes. With this context and
these goals in mind, we moved forward to test our hypotheses.
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3 MATERIALS AND METHODS
3.1 Hepatoma Experiments
The following section pertains to materials and methods used in hepatoma
experiments discussed in Chapter 4.
3.1.1 Cell Line and Culture Conditions
The mouse hepatoma line Hepal-6 was obtained from the ATCC (Manassas, VA)
and maintained in DMEM containing 25 mM glucose, 4 mM glutamine, and
supplemented by 10% (vol/vol) fetal bovine serum (FBS) (Sigma, St. Louis, MO) and 1%
(vol/vol) penicillin/streptomycin (PS) (Gibco). Confluent cells grown in this medium
were used to investigate the effects of removing glutamine from the medium for 24 h
followed by glutamine repletion to 4 mM and incubation for 24 h (Fig. 3.1). The
transcriptional and metabolic activities of cells undergoing this 48-h glutamine
depletion/repletion protocol were compared to control cells maintained in 4 mM
glutamine for the entire 48 h. To reduce the unknown amount of hormones and
endogenous lipids in the medium during the 48-h glutamine depletion/repletion, FBS was
replaced with 10% Controlled Processed Serum Replacement 3 (CPSR3) (Sigma) in both
the control and experimental samples. Metabolites and actinomycin D were obtained
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Figure 3.1. Incubation protocol for glutamine oscillations in
hepatoma cells.
from Sigma. Stable isotopes were purchased from Isotec (Miamisburg, OH) and
radioisotopes from American Radiolabeled Chemicals (St. Louis, MO).
3.1.2 Isotopic Metabotite Flux Assays
Isotopic metabolic flux assays were conducted at specified intervals across the 48-
h glutamine depletion/repletion protocol. Fluxes were monitored as the release of labeled
atoms from labeled glucose as it was metabolized, either 3H2 0 from 3H-labeled glucose
or 4CO2 from 14C-labeled glucose. The forward flux of hexose-phosphate isomerase was
estimated from release of 3H2 0 from [2-3H] glucose while the flux through the normally
irreversible glycolytic step, phosphofructokinase, followed by triose-phosphate isomerase
was estimated from release of 3H2 0 from [3-3H] glucose. The flux through pyruvate
dehydrogenase (PDH) was monitored by 14CO2 production from [3,4-14C] glucose. The
oxidation of glucose in the TCA cycle was monitored by 4CO2 production from [6-14C]
glucose. It should be noted that flux estimates using these labeled precursors supplied
exogenously do not include flux of pre-existing intracellular metabolites through the
same reactions. Modifications of the traditional versions of these assays (23) were
developed to allow the assays to be performed in a higher throughput 96-well format and
to limit the incubation time for the assays to 1 h. The absolute flux values of these assays
varied between experiments, but were self-consistent within each experiment. The
absolute flux values may not compared between experiments or between assays.
At specified intervals, the medium prescribed by the glutamine depletion/repletion
protocol was removed from designated wells and replaced with isotope flux assay
medium consisting of DMEM modified to contain 0.6 mM glucose and 1 mM glutamine.
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In addition, each well contained 0.1 - 0.2 pCi of one 3H- or 14C-labeled glucose isotope
at a specific activity of 0.8 to 1.6 Ci/mole. To quantify 3H20 production from 3H-labeled
glucose, the traditional assay using a borate resin to trap the labeled glycolytic
compounds (46) was modified for use in a 96-well format. After a 1-h incubation with
isotopes in the 96-well plate, the medium was removed and dispensed onto 0.4 ml of
Dowex 1 x 400 borate resin (Sigma) in Spin-X centrifuge filter tubes (Costar). The tubes
were agitated, incubated for 30 minutes, and centrifuged for 5 minutes at 5,000 rpm. The
filtrate, which contained the 3H20, was quantified by liquid scintillation counting.
To allow for 14 CO2 collection, breakaway 96-well clusters (Costar) were used for
the 14C-glucose studies. To measure the 14CO 2 produced, individual wells were
suspended in a 7 ml scintillation vial and gassed with 95/5 O2/CO 2 immediately
following addition of the 4C-glucose the wells. The vial was then closed with a rubber
septum cap and incubated for 1 h at 37°C. After the 1-h incubation, a syringe deposited
-20 of 30% perchloric acid through the septum into the well to terminate metabolic
activity. A second syringe delivered 0.2 ml of hyamine hydroxide (ICN Pharmaceuticals,
Costa Mesa, CA) to the bottom of the scintillation vial to absorb the CO2. The trapped
14CO2 was quantified by liquid scintillation counting.
3.1.3 13C Metabolite Pool Measurements
Metabolite pools were measured using a GC/MS method that included the
addition of heavy 13 C-labeled internal standards at the time of cell lysis. The internal
standards were heavy 3C-labeled versions of each compound to be quantified. The area
of each internal standard was compared to its naturally labeled counterpart. At the time
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of the assay, metabolism was terminated with addition of 3 ml of 2% perchloric acid. The
internal standards were added. Intracellular anions and cations were isolated by ion-
exchange chromatography (203). These fractions were dried and derivatized with N-
Methyl-N-[tert-butyldimethylsilyl]trifluoroacetamide + 1% tert-
butyldimethylchlorosilane (MTBSTFA + 1% TBDMCS) (Pierce, Rockford, IL). Seventy
microliters of MTBSTFA + 1% TBDMCS and 50 jil of dimethylformamide (DMF)
(Pierce) were added to the dried sample. The sample was then capped, vortexed, and
heated at 70°C for 30 min. The samples were analyzed with a Varian model Saturn 2000
GC/MS in electron ionization mode. One microliter of each sample was injected onto a
30 m CP-SIL 8 CB low bleed column (Varian, Walnut Creek, CA). The GC oven
temperature was held at 140°C for 2 minutes after sample injection, before increasing it
at a rate of 3°C/min to a final temperature of 250°C. This final temperature was held for
6.33 min for a total run time of 45 min.
3.1.4 3H20 Lipogenesis Indicator Assay
Total lipid synthesis was estimated by the 3H2O incorporation method (103) using
a protocol designed for cultured cells (22) and modified for a 1-h incubation. Cells in 6-
well plates were incubated as prescribed by the glutamine depletion/repletion protocol.
At 4-h intervals, the medium in individual wells was replaced with isotope flux assay
medium containing 2-3 mCi 3H20 in 1.5 ml. The assay was terminated with 2%
perchloric acid. Saponifiable lipids were extracted and quantified by liquid scintillation
counting.
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3.1.5 Isotopomer Spectrat Anatysis
Isotopomer Spectral Analysis (ISA) provides a method for quantifying the sources
of carbon for de novo lipogenesis using stable isotope incorporation into products and
analysis by nonlinear regression (87). As shown in Figure 3.2, a 13 C-labeled substrate
(on all carbons) is introduced into the incubation. This substrate is metabolized to 13C-
labeled acetyl-CoA (on both carbons), which mixes with naturally labeled acetyl-CoA in
the precursor pool. Eight units of acetyl-CoA are polymerized to form newly synthesized
palmitate. The labeling pattern of the newly synthesized palmitate will reflect the
percentage of acetyl-CoA that is 13C-labeled, which we call D. Pre-existing palmitate in
the cell mixes with this new palmitate. The labeling pattern of the pre-existing palmitate
will reflect natural labeling of carbon, hydrogen, and oxygen. The mixed palmitate that
we assay at a certain time point will yield a labeling pattern that reflects a weighted
average of the newly synthesized and pre-existing labeling patterns. These weights
reflect the percentage of palmitate that is newly synthesized, which we call g(t).
Unlike the -h radioisotope assays, ISA was performed over a 24-h period to
estimate the overall effect of glutamine depletion on lipogenesis. Cells were
preincubated for 24 h in media with 4 mM or 0 mM glutamine and then transferred to
media containing one 3C-labeled substrate for an additional 24 h. Control cells were
evaluated in media containing 25 mM glucose and 4 mM glutamine with either [U-3C]
glucose (25 mM) or [U-13C] glutamine (4 mM). This allowed estimation of the roles of
both glucose and glutamine as lipogenic precursors. Glutamine-depleted cells were
evaluated in media containing [U-13C] glucose (25 mM). Following the 24-h incubation,
the experiment was terminated with perchloric acid and cells were processed for ISA.
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Figure 3.2. Isotopomer Spectral Analysis schematic. Labeled substrates are
metabolized to acetyl-CoA and mix with natural acetyl-CoA. The acetyl-
CoA is polymerized to newly synthesized palmitate, which mixes with pre-
existing palmitate. Analysis with GC/MS measures the isotopomer
distribution of the mixed palmitate pool.
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Total lipids were extracted into 3:2 hexane:isopropanol (67), containing heptadecanoic
acid (20 pig per well) as an internal standard for quantification of fatty acids. After
solvent evaporation, the residue was treated with BF3/MeOH (14%) to derivatize total
fatty acids as methyl esters (72). Methyl esters were dissolved in DMF before analysis
by GC/MS. Mass isotopomer analysis focused on palmitate to determine the ISA
parameters D, the fractional contribution of the labeled substrate to the lipogenic acetyl-
CoA, and g(24 h), the fraction of newly synthesized fatty acid present after 24 h.
3.1.6 DNA Microarray Experimental Protocol
Cells were seeded onto T25 flasks for the DNA microarrays and onto 96-well
breakaway clusters for the hexose isomerase flux indicator assay. Data were taken at the
following time points: 0.5, 12, 18, 24, 36, 39, and 48. At each time point, the cells were
assayed for hexose isomerase flux and for mRNA expression. The protocols for the RNA
extraction, labeling of probes, hybridization, and printing of arrays are listed at the Gene
Expression Omnibus: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi, with the accession
numbers GSE404, GPL285, and GSM5974 - GSM5993. The resulting data were
downloaded and formatted in Excel (Microsoft, Redmond, WA), and then analyzed using
Matlab (The MathWorks, Inc., Natick, MA). The DNA microarrays were performed
with duplicate flasks of cells for each condition and each time point. Any unacceptable
data points, flagged by scanning software were eliminated. The data in the duplicate
arrays were then merged and averaged to create a union data set. Genes were retained in
the union set only if data were available for each of the 7 time points. To capture genes
with significant changes in gene expression, the data were filtered to eliminate genes that
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did not have at least one time point with a log2 ratio greater than 0.6 or less than -0.6.
These values were selected to insure 95% confidence for significant expression changes.
Previous validation studies (not shown) demonstrated that the median coefficient of
variation across duplicate arrays was 10.2%.
3.2 Hepatocyte Experiments
The following section pertains to materials and methods used in hepatocyte
experiments discussed in Chapters 5 and 6.
3.2.1 Reagents and Materials
Bovine insulin, dexamethasone, glucagon, Dulbecco's modified Eagle's medium
powder (DMEM), fetal bovine serum (FBS), and other cell culture reagents were
purchased from Sigma (St. Louis, MO). [6-3H] glucose was purchased from American
Radiolabeled Chemicals (St. Louis, MO). Stable isotopes (D20, [U-13C] glycerol) were
purchased from Cambridge Isotope Laboratories (Andover, MA).
3.2.2 Animats
Male C57/BL6 mice were obtained from Taconic (Germantown, NY). Animals
were housed in a facility approved by the American Association for Accreditation of
Laboratory Animal Care. All animals received humane care in compliance with
institutional guidelines. Mice had free access to water and chow ad libitum before the
study. Mice were between 7 and 12 weeks old and 25-32 g body wt at their time of
sacrifice.
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3.2.3 Composition of Hepatocyte Medium Base
DMEM powder (Sigma) was supplemented with 3.7 g/L NaHCO3, 30 mg/L
proline, 100 mg/L ornithine, 610 mg/L niacinimide, 0.544 mg/L ZnCl2, 0.75 mg/L
ZnSO4.7H20, 0.2 mg/L CuSO4.5H 20, 0.025 mg/L MnSO4, 146 mg/L glutamine, 2 g/L
bovine serum albumin, 100,000 units/L penicillin, and 100,000 tg/L streptomycin. The
medium was sterilized by filtration through a 0.22 im filter and stored at -20°C.
Hormones, glucose, and fetal bovine serum were added to this base medium as specified
by the incubation protocol.
3.2.4 Mouse Hepatocyte Isolation
Mouse hepatocytes were prepared for primary culture by nonrecirculating
collagenase perfusion, as adapted from Seglen (165). In brief, the mouse was
anesthetized with Avertin at a dose of approximately 0.025 ml Avertin/g body weight.
The liver was initially infused with Ca2+-free perfusion buffer and then dissociated with
collagenase type IV (100 units/ml; Sigma). Isolated hepatocytes were scraped from the
liver sac in preservation buffer. Hepatocytes were filtered through a 100 ptm nylon mesh
filter and then a 70 ,m. The cell suspension was centrifuged at 50 x g, resuspended with
33% Percoll (GE Healthcare, Piscataway, NJ) and centrifuged at 50 x g. The pellet was
resuspended in preservation buffer and centrifuged again at 50 x g. The resulting cell
pellet was resuspended in Attachment medium, counted, and tested for viability using
trypan blue exclusion. Cells were usually 85% to 90% viable.
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3.2.5 Mouse Hepatocyte Culture
Primary mouse hepatocytes were seeded onto Type I collagen-coated tissue
culture plates (BD Biosciences, Bedford, MA) in Attachment medium (Hepatocyte
Medium Base supplemented with 1 nM insulin, 100 nM dexamethasone, 7% FBS, and 10
mM glucose). Glycogen synthesis experiments used 6-well plates with a density of 1.5 x
106 cells/well in 1.5 ml of Attachment medium. Glucose production and intracellular
flux experiments used 12-well plates with a density of 6.1 x 105 cells/well in 600 pl of
Attachment medium. Metabolite profiling experiments used T12.5 flasks with a density
of 2.0 x 106 cells/flask in 2.0 ml of Attachment medium. The cells were allowed to attach
for 1 h at 37°C in a humidified atmosphere containing 5% CO2. Cells were then washed
with PBS and given Maintenance medium (Hepatocyte Medium Base supplemented with
5 nM insulin, 100 nM dexamethasone, 7% FBS, and 20 mM glucose). 6-well plates
received 1.0 ml/well, 12-well plates received 400 pl/well, and T12.5 flasks received 1.3
ml/well. After 24 h, cells were washed with PBS and given Preincubation medium
(Hepatocyte Medium Base supplemented with 1 nM insulin, 100 nM dexamethasone, and
5 mM or 20 mM glucose). The medium volumes were identical to those given for
Maintenance medium. Any modulators (glucosamine, azaserine, and alloxan) to be used
were also added at this time. Cells were treated in the Preincubation medium for 16 to 18
h. For metabolite profiling experiments, a reference treatment of Preincubation medium
with 1 mM glucose and no modulators was included.
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3.2.6 Anatysis of Glycogen Synthesis
After treatment in Preincubation medium, cells were incubated for 1 h in 1.0 ml of
Glycogen Assay medium (Hepatocyte Medium Base supplemented with 25 nM or 0 nM
insulin) (Fig. 3.3A). 5 mM glucose was then added to the Assay medium, spiked with 2
pCi [6-3H] glucose (60 Ci/mmol), for a period of 2 h. The analysis of glycogen synthesis
was adapted from Kaibori et al. (84). After 2 h, the experiment was terminated by
aspirating the medium and washing the cells twice with ice-cold PBS. Cells were
solubilized with 0.5 ml 30% KOH for 1.5 h. 0.4 ml of each sample was transferred to
tubes and heated at 70°C for 20 min. 50 pl of glycogen carrier (25 mg/ml), 50 pl of
saturated NaSO4, and 1.4 ml of ethanol were added to the tubes. Samples were kept
overnight at -20°C. Precipitated glycogen was centrifuged at 3,000g for 10 min. Pellets
were resuspended in 0.4 ml water, heated at 70°C for 20 min, and reprecipitated with 1.5
ml ethanol. After 0.5 h at -20°C, precipitated glycogen was centrifuged at 3,000g for 10
min. Pellets were resuspended in 0.5 ml water and counted by scintillation counting.
The glycogen deposition data represent the flux of radiolabeled extracellular
glucose to glycogen. The term "insulin sensitivity" was used during comparisons
between treatments with insulin in the Assay medium. A change in sensitivity was
considered significant if the difference between the glycogen deposited in the two insulin
treatments was significant (P < 0.05).
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ADay Day 
B
Figure 3.3. Protocols for analysis of glycogen synthesis (A)
and analysis of glucose production (B). Both protocols are
identical up to the completion of Day 2. On Day 3, different
protocols are followed for the assay of glycogen synthesis and
glucose production.
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3.2.7 Anatysis of Glucose Production
After treatment in Preincubation medium, cells were incubated for 1 h in 400 gl
of Glucose Assay medium (Hepatocyte Medium Base supplemented with 10 nM
glucagon, or 25 nM insulin) (Fig. 3.3B). At the end of the 1 h incubation (t = 0 h), 0.4 ml
of medium were taken for analysis from a subset of samples treated with 25 nM insulin.
The remaining samples then had 9 mM lactate/0.9 mM pyruvate, or 1.5 mM glycerol and
9 mM lactate/0.9 mM pyruvate added to their Assay medium, depending on the specific
experiment. After a 2 h incubation (t = 2 h), 0.4 ml of medium were taken from each
sample for analysis. Glucose and lactate concentrations were measured by a YSI 2700
Select glucose/lactate analyzer (YSI Inc., Yellow Springs, OH). The glucose measured at
t = 0 h was subtracted from every sample measured at t = 2 h in order to eliminate any
residual glucose from the Preincubation medium.
The term "insulin sensitivity" was used during comparisons between treatments
with insulin in the Assay medium. A change in sensitivity was considered significant if
the difference between the glucose produced in the two insulin treatments was significant
(P < 0.05).
3.2.8 Metabotite Profiling
Immediately after treatment in Preincubation medium, the metabolites were
isolated and analyzed with a method used by Fiehn et al. (53) (Fig. 3.4A). Briefly, the
medium was removed and the cells were lysed with 0.7 ml methanol. An internal
standard of ribitol was added at this time (4 gg/sample) to correct for sample loss and
differences in derivatization efficiency between samples. Water (0.7 ml) was added to
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Figure 3.4. Protocols for metabolite profiling (A) and
measurement of intracellular fluxes (B). Both protocols are
identical up to the completion of Day 2. On Day 3, different
protocols are followed for the assay of metabolite levels and
intracellular fluxes.
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the lysate and 0.38 ml chloroform was used to extract nonpolar metabolites. The
remaining metabolites were dried in a vacufuge. To derivatize the metabolites, we added
50 p.1 of methoxyamine hydrochloride (20 mg/ml pyridine) to each sample and incubated
for 90 min at 30°C. Then we added 80 p.l of MSTFA + 1% TMCS (Pierce, Rockford, IL)
to each sample and incubated at 37°C for 30 min. The samples were analyzed with a
Varian model Saturn 2000 GC/MS in electron ionization mode. One microliter of sample
was injected onto a 30-m CP-SIL 8 CB low-bleed column (Varian, Walnut Creek, CA).
The GC oven temperature was held at a 70°C for 5 min after sample injection, before
increasing at a rate of 5°C/min to a final temperature of 265°C. This final temperature
was held for 1 min for a total run time of 45 min. During analysis of each sample, the
area under the curve for each metabolite was normalized by the area of the ribitol peak
for that sample to account for sample loss during processing. Each metabolite's
normalized area was then divided by that metabolite's normalized area in the reference
state (1 mM glucose, no modulators), which was run with every profiling experiment.
3.2.9 Stabte Isotope Labeling of Glucose
After treatment in Preincubation medium, cells were treated for 2 h in 400 Rl of
Stable Isotope Assay medium (Hepatocyte Medium Base supplemented with 9 mM
lactate, 0.9 mM pyruvate, and 10 nM glucagon or 25 nM insulin). In two different
experiments, the Stable Isotope Assay medium was supplemented with 10% D20 (no
glycerol) and 1.5 mM [U-13C] glycerol (Fig. 3.4B). At the end of the 2 h incubation, the
medium from each sample was aspirated and stored at -20°C until analysis. This
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protocol differs from the glucose production experiments in that there was no -h
incubation period with the hormones.
3.2.10 Derivatization of Glucose
In both experiments, the samples were analyzed by quantifying the relative
abundances of the isotopomers from several glucose fragments. To obtain as many
glucose fragments as possible, we employed three different derivatization schemes to
analyze the labeled glucose: aldonitrile pentapropionate, methyloxime pentapropionate,
and di-O-isopropylidene propionate.
Briefly, the aldonitrile pentapropionate method was performed as follows. One
hundred microliters of sample were mixed with 300 pl of cold acetone. The mixture was
vortexed and then centrifuged at 14,000 rpm for 5 min. The supernatant was collected
and then dried under airflow at 60°C. Fifty microliters of hydroxylamine hydrochloride
in pyridine solution (20 mg/ml) were added to the sample, which was incubated at 90°C
for 60 min. One hundred microliters of propionic anhydride were added to the sample,
and the sample was incubated at 60°C for 30 min. The sample was dried under airflow at
60°C, and dissolved in 100 p1 of ethyl acetate. The methyloxime pentapropionate
method employed the same steps as listed for aldonitrile pentapropionate derivatization,
except that a methylhydroxylamine hydrochloride in pyridine solution (20 mg/ml) was
used instead of hydroxylamine hydrochloride solution.
Briefly, the di-O-isopropylidene propionate was performed as follows (64). One
hundred microliters of sample were mixed with 300 l of cold acetone. The mixture was
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vortexed and then centrifuged at 14,000 rpm for 5 min. The supernatant was collected in
screw-top glass tubes and then dried under airflow at 60°C. Five hundred microliters of
0.38 M sulfuric acid in acetone were added to the dried samples. The samples were
vortexed and left at room temperature for 60 min. The reaction was stopped by adding
400 pl of 0.44 M sodium carbonate. Then ml of saturated sodium chloride solution and
1 ml of ethyl acetate were added. The samples were vortexed for 15 seconds, and then
left alone for phase separation. The top organic layer was collected in Eppendorf tubes,
and dried under airflow at room temperature. One hundred and fifty microliters of
propionic anhydride/pyridine solution (2:1 propionic anhydride/pyridine, v/v) were added
to each sample, and the samples were incubated for 30 min at 60°C. The sample was
dried under airflow at 60°C, and dissolved in 00 pl of ethyl acetate.
The D 20 samples were derivatized by the aldonitrile pentapropionate method and
the methyloxime pentapropionate method. The [U-13C] glycerol samples were
derivatized by the aldonitrile pentapropionate and di-O-isopropylidene propionate
methods.
3.2.11 GC/MS Analysis of Glucose
All samples were then analyzed on a Hewlett Packard 5890 Series II GC
connected to a Hewlett Packard 5971 Series MS in electron ionization mode. One
microliter of sample was injected onto a 60-m DB-XLB column (J & W Scientific,
Folsum, CA). The GC oven temperature was held at 80°C for min after sample
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injection, before increasing at a rate of 20°C/min to a final temperature of 280°C. This
final temperature was held for 4 min for a total run time of 15 min.
3.2.12 Analysis of GC/MS Data
The analysis of the D20 data was as follows. The isotopic abundances were
quantified for the fragment of glucose with the m/z ratio of 145 for the methyloxime
method. The isotopomers quantified were 145-148 m/z. For the aldonitrile method, the
isotopic abundances were quantified for the fragments of glucose with the m/z ratios of
173, 259, 284, and 370. The isotopomers quantified were 173-176, 259-263, 284-288,
and 370-374 m/z.
The analysis of the [U-13C] glycerol data was as follows. The aldonitrile
pentapropionate method was analyzed differently from the D20 data, and the isotopic
abundances of glucose fragments 173 and 370 m/z were quantified. The isotopomers
quantified for the 173 fragment were 173-178 and 370 to 377 m/z. For the di-O-
isopropylidene propionate method, the isotopic abundances were quantified for the
fragment of glucose with the m/z ratio of 301. The isotopomers quantified for the 301
fragment were 301-309 m/z.
3.2.13 Metabolic Network Model
The reactions in our gluconeogenesis model are shown in Figure 3.5. The network
model contains two gluconeogenic precursors, i.e. oxaloacetate and glycerol.
Oxaloacetate is the common intrahepatic precursor to glucose, which is first converted to
phosphoenolpyruvate by the irreversible phosphoenolpyruvate carboxykinase (PEPCK).
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Figure 3.5. Metabolic network model for gluconeogenesis. This shows
the full set of reactions used in the Metran calculations.
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The PEPCK flux represents here the combined gluconeogenic contribution from lactate,
pyruvate, glutamine, TCA cycle intermediates and related metabolites. We included
glycerol's contribution to glucose explicitly in the model, allowing us to model isotope
incorporation from glycerol to glucose. Glycerol is believed to contribute 10-30% to
glucose production in vivo (96). Breakdown of endogenous glycogen, i.e. glycogenolysis,
is an alternative pathway for glucose production in hepatocytes, and is modeled here by
two reactions, i.e. phosphorylase and phosphoglucomutase. In our model, the reversibility
of any reaction was assigned based on current knowledge. Many of the linear pathways
in our model were lumped into single reactions, resulting in the flux map in Figure 6.1.
Furthermore, we assigned absolute stereochemistry to all reactions based on
current knowledge. It has been long known that biochemical reactions are highly
stereospecific (155), i.e. enzymes differentiate between prochiral hydrogen atoms and
other prochiral groups. It is therefore important that we keep track of all prochiral
hydrogen atoms in the model and assign stereospecific atom transitions for them. The
absolute stereochemistry for many reactions has been worked out in detail. For example,
it is known that phosphoglocose isomerase (PGI) abstracts specifically the pro-R
hydrogen at C-1 of fructose 6-phosphate (F6P) (106, 107, 164) and transfers it to the C-2
position of glucose 6-phosphate (G6P), however, hydrogen exchange with the solvent is
also observed in this conversion. Malaisse et al. reported for a single passage in the
direction F6P -- G6P, 65% intramolecular hydrogen transfer and 35% hydrogen
exchange, and for a single passage in the direction G6P - F6P, 72% intramolecular
hydrogen transfer and 28% hydrogen exchange. Triose phosphate isomerase (TPI) has the
same stereochemistry as PGI. Phosphomannose isomerase (PMI), on the other hand, is
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Table 3.1. Stoichiometry and atom transformations for gluconeogenesis model in Fig. 3.5.
No. Enzyme Stoichiometry Atom transformations*
Upper gluconeogenesis
1 glucose 6-
phosphatase
2 phosphoglucose
isomerase
3 fructose 1,6-
bisphosphatase
4 aldolase
5 triose phosphate
isomerase
6 phosphomannose
isomerase
7 transketolase
Glycogenolysis
8 phosphorylase
9 phosphoglucomutase
G6P -- Gluc
F6P + 0.3 H + G6P + 0.3 H
FBP -> F6P
DHAP + GAP - FBP + H
DHAP + 0.3 H o GAP + 0.3 H
F6P + H -> M6P + H
F6P <-> E-C2 + E4P
Glycogen -> G1P
G1P -> G6P
abcdef-> abcdef
abcdef abcdef
(70%) C1-HPr° R -' C2-H
(30%) C1-HP° R + H + H + C2-H
abcdef-> abcdef
abc + def -+ cbadef
(DHAP)C 1 -HP °S > H
abc <-> abc
(70%) C1-HPr° R - C2-H
(30%) C1-HPr °R + H <-> H + C2-H
abcdef-> abcdef
Cl-HPr °S + H -> H + C2-H
abcdef - ab + cdef
abcdef-> abcdef
abcdef - abcdef
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* For each compound carbon atoms are identified using lower case letters to represent
successive carbon atoms of each compound.
Table 3.1 Continued. Stoichiometry and atom transformations for gluconeogenesis model
in Fig. 3.5.
No. Enzyme Stoichiometry Atom transformations*
Glycerol metabolism
10 glycerol kinase
11 glycerol 3-phosphate
dehydrogenase
Lower gluconeogenesis
12 glyceraldehyde 3-
phosphate
dehydrogenase
13 phosphoglycerate
kinase
14 phosphoglycerate
mutase
15 enolase
16 phosphoenolpyruvate
carboxykinase
Hydrogen incorporation into
17
18
19
20
21
Glyc -- Glyc3P
Glyc3P *- DHAP + NADH
BPG + NADH 4 GAP
3PG <- BPG
2PG <- 3PG
PEP+ H - 2PG
OAC -- PEP + C02
abc -4 abc
abc - abc
C2-H - NADH
abc <-> abc
NADH 4 C 1 -H
abc <- abc
abc <- abc
abc <-> abc
H <- C2-H
abcd -> abc + d
oxaloacetate and NADHfrom endogenous sources
OAC + H --> OAC + H abcd -> abcd
C3-HPr °S + H <-+ H + C3-HPr°s
OAC + H - OAC + H abcd- abcd
C3-HPr° R + H - H + C3-HproR
H -> NADH H-NADH
unlabeled -- NADH Hunlabeled -> NADH
NADH -> other NADH - H the r
81
* For each compound carbon atoms are identified using lower case letters to represent
successive carbon atoms of each compound.
known to have the opposite stereochemistry, i.e. PMI specifically abstracts the pro-S
hydrogen. Furthermore, no intramolecular hydrogen transfer has been observed for this
reaction, and thus the hydrogen at C-2 of mannose 6-phosphate (M6P) always originates
from the medium. Table 3.1 summarizes the assumed stereochemistry for all reactions in
our model.
3.2.14 Estimation of Intracellular Fluxes
Metabolic fluxes and their confidence intervals were determined by simultaneous
fitting of mass isotopomer abundances of glucose fragments to a detailed metabolic
network model of hepatocytes using the software Metran (Maciek Antoniewicz,
manuscript submitted). In short, Metran estimates fluxes by minimizing the difference
between the observed and simulated measurements using an iterative least-squares
minimization procedure. The objective of this routine is to evaluate a set of feasible
fluxes that best accounts for the observed isotopomer and extracellular flux
measurements. After metabolic fluxes were calculated, statistical analysis was
automatically performed to obtain accurate standard deviations and 95% confidence
intervals of fluxes by evaluating the sensitivity of the objective function with respect to
fluxes as described in (Maciek Antoniewicz, manuscript submitted). Flux validation was
accomplished by a statistical test for the goodness-of-fit based on the chi-square test for
model adequacy (Maciek Antoniewicz, manuscript submitted). To ensure a global
solution, flux estimation was repeated at least four times starting with random initial
values. All computations were performed with Matlab 6.5 using Matlab Optimization
Toolbox (Mathworks Inc.).
82
3.2.15 Statistics
Glycogen deposition and glucose production data were analyzed using a Student's
t test (Microsoft Excel) to compare the means from experimental groups. P < 0.05 was
considered statistically significant. In cases where multiple groups were all compared to
a single group, the Dunnett's test for multiple comparisons was applied (57).
Besides fluxes, Metran also generates the standard deviations for the relative
intracellular fluxes estimated. The standard deviation of the absolute intracellular flux (c)
was calculated by combining the standard deviation of the relative intracellular flux (b)
and the glucose production measurement (a) according to the following equation:
C =C - +
where (A + a) x (B + b) / 100 = (C + c) and A x B / 100 = C.
The correlational analysis of the absolute intracellular flux maps examined the
possible relationship of glucose production to each absolute intracellular flux. Each data
set consisted of 32 pairs of data each comprising an intracellular flux along with the
corresponding glucose production for the various conditions examined. The exception
was the glycerol uptake flux (flux 3 in Fig. 6.1), for which only 16 pairs of data were
obtained. A weighted linear regression was performed for each glucose production-
intracellular flux pairing using all the data points for each of the 5 intracellular fluxes as
independent variables and the glucose production as the dependent variable, as shown by
Press et al. (145). The data points were weighted by the standard deviations in the
glucose production, which had an average coefficient of variation (COV) of 10.3%. The
error in the absolute intracellular fluxes was ignored because the average COV in the
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relative flux data was 2.1%. The standard deviations for the slope and the intercept of the
best-fit line were also calculated.
Once the best-fit line for each flux/glucose production combination was found, we
tested the hypothesis that breaking the data into two different groups would lower the
weighted sum of squared residuals significantly. The groupings were chosen according
to glucose level in the Preincubation medium, insulin or glucagon treatment in the Assay
medium, and presence of glycerol in the Assay medium. We did not break the data into
smaller groups because we felt the sample size for regression would be too small. To
accept the two-group regression over the single-group regression, the following criterion
had to be fulfilled for both subgroups:
SSall > F(df.um dfdenom .095)
SSsubgroup
where SSall is the weighted sum of squared residuals for the regression with all the data
points, SSsubgroup is the weighted sum of squared residuals for the regression with the
subgroup, and F is the F-statistic for the degrees of freedom specified in the numerator
(dfnum) and denominator (dfdenom) and a confidence interval of 95%. The dfnum was 30
because there were 32 data points and 2 parameters in the linear regression. The dfdenom
was 14 because there were 16 data points and 2 parameters in the linear regression. For
these parameters, the F-statistic was 2.31. Therefore, when the data set of 32 points was
broken into two sets of 16 data points, the decrease in the weighted sum of squared
residuals was required to be a factor of 2.31 for both data sets in order to accept the two-
group regression over the single group regression. The R2 metric for each best-fit line
was calculated as follows:
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R = 
= 1 SSres
SStotal
where SSres = SSsubgrOup = SSa, was the weighted sum of squared residuals calculated from
the observed data to the regression line and SStotl was the weighted sum of squared
residuals calculated from the observed data to a horizontal line situated at the mean of the
dependent variable values.
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Appendix
Hepatocyte Media Formulation
Block et al., J Cell Biol (1996) 132(6):1133-1149
This medium is DMEM powder base with sodium bicarbonate added. Then more
components are added to make it more like Williams Medium E.
Base Medium
DMEM, no glucose, no sodium pyruvate, no glutamine, no phenol red; Sigma D-5030;
Stock Solutions
1. 200 g/L L-Ornithine. 50 ml ddH20, 10 g L-Ornithine (Sigma 0-6503). 0.5 ml aliquot.
2. 305 g/L Niacinimide. 200 ml ddH2 O, 61 g Niacinimide (Sigma N-0636). 1 ml aliquot.
3. Trace Metals solution
1.088 g/L ZnC12 0.0544 g ZnCl2 (Sigma Z-0152)
1.500 g/L ZnSO4.7H20 0.075 g ZnSO4-7H20 (Sigma Z-0251)
0.400 g/L CuS04 -5H2O - 0.020 g CuSO4 .5H20 (Sigma C-8027)
0.050 g/L MnSO4 0.0025 g MnSO4 (Sigma M-7634)
Dissolve in 50 ml 1 x PBS. 0.5 ml aliquot.
4. Aliquot Penicillin/Streptomycin into 10 ml aliquots (Sigma P-0781).
5. 2 RM Bovine Insulin. Weigh out 10 mg insulin (Sigma 1-6634). Add 1.5 ml sterile
water. Add glacial acetic acid until insulin dissolves (- 140 pl). Add more water to
make the volume 2 ml. Add the 2 ml to 85.2 ml water to make a 20 pM solution. Dilute
4 ml of that solution in 36 ml water to make 2 M solution. ml aliquot.
6. 0.127 mM Dexamethasone. Dissolve 1 mg dexamethasone (Sigma D-8893) in 1 ml
ethanol using sterile syringe and needle. After powder is dissolved, add 19 ml PBS, mix
thoroughly. 800 p1 aliquot. Expires 3 months from date of reconstitution.
Formulate 0 mM glucose Hepatocyte Growth Medium Base
1. Add 680 ml of ddH2O to 1 bottle of powdered DMEM base (Sigma D-5030).
2. While stirring the DMEM base solution, add 3.7 g of sodium bicarbonate.
3. Add stock solutions:
0.5 ml of 60 g/L L-Proline
0.5 ml of 200 g/L L-Ornithine
2.0 ml of 305 g/L Niacinimide
0.5 ml of Trace Metals solution
4. Add 0.146 g Glutamine (Sigma G-8540).
5. Add 2 g Bovine Serum Albumin (Sigma A-9647).
6. Add 10 ml Penicillin/Streptomycin.
7. Adjust medium pH to 7.35 with 10 M HC1.
8. Sterile filter the medium and dispense 40 ml aliquots. Store at -20°C.
9. Add components according to media spreadsheet.
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Collagen Coating Protocol
1) Dilute Type I collagen with 0.1% acetic acid to 200 pig/ml. Sterile filter. Start with
100% acetic acid. Dilute 200 pl in 200 ml ddH20.
2) Dispense into tissue culture dishes 40 p.L/cm2.
6-well plate 9.61 cm2 384.4 pl - 400 pl
12-well plate 3.8 cm2 152 pl - 150 pl
24-well plate 2.0 cm2 80.0 p1 - 75 pl
96-well plate 0.32 cm2 12.8 1l - 30 pl (to cover well)
35 mm dish 9.62 cm 2 384.8 pI - 400 gl
60 mm dish 28.27 cm2 1,130.8 pl - 1200 plt
T12.5 flask 12.5 cm2 500 pl - 500 l
T25 flask 25 cm2 1000 pl - 1000 pi
3) Shake the plates to ensure full coverage of all wells.
4) Shake plates again to ensure coverage. Aspirate any extra liquid.
5) Air-dry dishes at RT in the biosafety cabinet overnight (no UV).
6) When dry, seal dishes in plastic bags and store at RT. Good for 3 months.
This procedure gives a coating of about 4-8 pg collagen/cm2.
Cell Attachment and Preincubation Protocol
1) Seed cells on type I collagen-coated substrates in correct volume of Attachment
Medium (1.5 x the correct amount for flask/plate).
T25 flask 4.0 x 106 cells 2.65 ml - 4.0 ml
T12.5 flask 2.0 x 106 cells 1.32 ml - 2.0 ml
6-well plate 1.5 x 106 cells 1.02 ml 1.5 ml
12-well plate 6.1 x 105 cells 403 pl - 600 pl
24-well plate 3.2 x 105 cells 187 .l 300 tl
96-well plate 5.1 x 104 cells 34 pl - 60 p1
2) Wait 40-60 minutes, and then aspirate medium.
3) Wash with PBS.
4) Dispense specified amount of Maintenance Medium and incubate overnight.
T25 flask 4.0 x 106 cells 2.65 ml 2.6 ml
T12.5 flask 2.0 x 106 cells 1.32 ml - 1.3 ml
6-well plate 1.5 x 106 cells 1.02 ml 1.0 ml
12-well plate 6.1 x 0 5 cells 403 pl - 400 p1
24-well plate 3.2 x 105 cells 187 .l - 200 p.1
96-well plate 5.1 x 104 cells 34 p1 - 40 pt1
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GC/MS Compound List with TMS derivatization
Compound Pure Extract Ions
1 Pyruvate 5.67 5.48 158, 174, 189
2 Lactate 5.76 5.63 147,191,219,234
3 Alanine 6.79 6.83 147,174,190,218,233
4 Butanoic Acid 8.75 147, 191,233
5 Valine 10.31 10.32 147, 203, 218, 24,262
6 Urea 11.67 147, 189
7 Leucine 12.18 147, 158, 232, 275
8 Proline 12.69 12.69 147, 170, 216,244, 260
9 Isoleucine 12.75 73, 158, 218,232, 260, 275
10 Glycine 13.05 147,174,211,248,276,291
11 Succinate* 13.58 13.53 147,226,247
12 Fumarate* 14.66 14.62 147,217,245,324
13 Serine 14.85 147, 188, 204, 218, 278,306,321
14 Threonine 15.53 147, 218, 291, 335
15 -Alanine 16.55 147, 174, 248, 290,305
16 Oxaloacetate 17.76 147, 202, 230, 261,290, 378, 452
17 Malate* 18.39 18.37 233,265,307,335,423
18 Methionine 18.89 128,176,219,250,293
19 Glutamine 18.92 18.92 147,156,230,258,346
20 Aspartate 19.14 147, 188,232,306, 334,349
21 Cysteine 19.88 147,218,220,294,322,337
22 a-Ketoglutarate* 20.60 20.55 147, 170, 198, 288, 304,320
23 Asparagin 20.95 147,188, 216, 305,331,405,420
24 PEP* 21.12 21.06 147,211,299,369,384
25 Phenylalanine 21.43 147, 192,218, 266, 294,309
26 Glutamate 21.49 21.50 156, 230, 246,348,363
27 Gluconate 22.19 147,204,291,420,583
28 Asparagine 22.62 147, 188, 231,258, 333,348
29 Ribitol* 23.93 23.92 147,217,243,319,395,422
30 G3P 24.00 24.09 147,211,253,299,328,341,384,400,415
31 Glucose- IP* 24.84, 28.38, 24.84 217, 232,305, 450
35.25
32 UDP-Glucose* 24.84, 28.38 24.84 217, 232, 305, 450
33 Ornithine 25.79 174, 187, 200,216, 258,315,330, 420
34 3PG 25.87 25.80 147, 227,299,357,387,431,459,474
35 GlucN-1P 25.9 25.9 172,189,217,232,316,434,450
36 Citrate* 26.05 26.02 273,309,347,375, 436,465
37 UDP-GlcNAc* 26.15 26.14 147,173,203,217, 299,329,404, 420
38 GlcNAc-IP* 26.15 26.14 147,173,203,217,299,329,404,420
39 Fructose 27.35 27.04, 27.25 217,307, 364
40 Glucose 27.68 27.61 157,217,274,291,319,374,415,464
41 Lysine 27.96 28.00 156,174,230,329,419,434
42 Gluconic Acid 28.70 147, 205,217,292,333,433
43 Glucosamine 28.26, 28.44 205, 242, 273,291,304,319,357, 447
44 Tyrosine 28.39 147, 179,218,280, 330,354
45 Myoinositol 29.80 189,221,255,318,345,362
46 Inositol 30.21 147, 217,318,393,432
47 GlucNAc* 31.0, 31.09 31.11 147, 171,202,243,274,319,333,359,417
48 Ribose-SP 31.73 31.79 217, 299,315,357, 403,459, 604,619
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49 Ribulose-5P 32.07 32.07 147,217,275,299,315,357,387,604,619
50 Tryptophan 33.43 202,218,291
51 Inositol-P 34.45 318,434
52 Fructose-6P* 35.23 35.31 217,299,315,357,373,387,403,433,459
53 Glucose-6P* 35.45, 35.70 35.51,35.67 147,191,217,299,357,387,721
54 GlucN-6P* 36.0,36.07 36.12 195,217,241,285,299,315,387,403,429
55 6P-Gluconate 37.04 36.93 217,244,271,299,315,333,357,387,461
56 GcNAc-6P* 37.73,37.96, 37.73, 299,315,357,387,404,433,459
38.33 37.96,38.33
Mouse Hepatocyte Isolation Protocol (Developed by Matthew Wong)
The 2-step collagenase perfusion procedure by Seglen (Seglen, 1976), either in situ or ex
vivo, is recommended. Blanching of the liver should be almost complete within a few
seconds of perfusing with the first buffer. Otherwise, the liver should be discarded. For
mouse, the perfusion times should be 15 minutes with the first buffer and 10 minutes with
the second buffer should be enough. The liver should be swollen and sufficiently
softened. The temperature of the liver should be maintained at 37°C throughout the
perfusion. After excision of the liver, the cell suspension should be kept at 0-4°C until
the cells are seeded in culture. A minimum viability of 85% and a minimum yield of at
least 1.5 x 106 cells/gram mouse is recommended. Avertin can be used for anesthesia.
A good reference is:
Pertoft H. and Smedsrod B. 1987. Separation and Characterization of Liver Cells, in: Cell
Separation: Methods and Selected Applications, vol. 4, Academic Press.
Solutions:
Perfusion Buffer Concentrate (PBC)
1) Make 300 ml of 1 M NaOH (12 g NaOH).
2) Dissolve NaCI (103.75 g), KCI (6.25 g), and HEPES (28.7 g) in H20
(350 ml) while stirring. When all have been dissolved, add 75 ml of 1
M NaOH. Add H2 0 to a total volume of 500 ml.
3) Sterile filter (0.2 ptm) the solution and divide into 20 ml portions.
Collagenase Buffer Concentrate (CBC)
1) Solution A: dissolve HEPES (72 g), NaCI (12 g), and KCI (1.5 g) in 1
M NaOH (198 ml).
2) Solution B: dissolve CaCl2-2H20 (2.1 g) in H20 to a total volume of
30ml.
3) Mix solution A and B while stirring. Be careful to add B drop by
drop.
4) Add H20 to a total volume of 300 ml.
5) Sterile filter (0.2 gm) and freeze the solution in portions of 20 ml.
Avertin Stock Solution
1) Mix 1 g tribromoethanol (Sigma #90710) with 0.63 ml Tert amyl
alcohol (Sigma #24048-6).
2) Store stock in a dark glass container with no plastics in the cover at
4°C for up to a year. Avertin can dissolve some plastics.
1) Preparation 1 day before
* Autoclave 1 L ofddH 20 for 30 minutes fluid at 121°C.
* Autoclave surgical tools, a slotted incubator shelf, two 250 ml Pyrex bottles, and a
1 L Pyrex bottle for 30 minutes with 40 of dry time at 121 °C.
2) Preparation on the day of isolation
* Thaw 1 tube of PBC (20 ml) and 1 tube of CBC (20 ml).
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* Go get 2 mice.
* Perfusion buffer: add 480 ml sterile ddH20 to 20 ml of PBC. Pour 250 ml into
sterile bottle. Add 0.5 ml of 0.5 M EDTA for final concentration of 1 mM EDTA.
* Preservation buffer: mix 250 ml of perfusion buffer with 675 mg glucose (15
mM) and 2.5 g BSA. Let BSA dissolve for 5-10 minutes with occasional mixing.
* Collagenase buffer: add 180 ml ddH20 for a total volume of 200 ml. Add 20,000
units of collagenase enzyme activity.
* Percoll solution: Add 1.3 ml of 10x Hank's Buffered Saline Solution to 11.7 ml of
Percoll.
* Check pH of all four solutions and adjust to pH 7.4 with 10 M HC1 or 5 M NaOH.
* Sterile filter all solutions except the Percoll and dispense into sterile bottles.
* Dilute 24 pl Avertin stock in a polypropylene tube with 2.0 ml sterile water.
* Run 10 ml 70% EtOH through perfusion apparatus to waste at 1 ml/min.
* Empty tubing by letting air pass through for 5 minutes.
* Run 20 ml sterile ddH20 through perfusion apparatus to waste at 1 ml/min.
* Empty tubing by letting air pass through for 5 minutes.
* Prepare the sterile hood with a petri dish, cell filters, cell lifter, and three 50 ml
tubes.
* Prepare waste basin, incubator shelf, tools, and magnifying glass.
* Prewarm perfusion buffer in 40°C bath and let the buffer circulate at lml/min.
* Prewarm the collagenase buffer as well.
* Pipet 25 ml preservation buffer into 100 mm Petri dish. Keep dish and bottle of
preservation buffer on ice.
3) Anesthesia
* The animal should not be excessively distressed prior to anesthetization. Get the
animal from its cage, place into chamber, and weigh the animal.
* Bring the animal (in the chamber) over to the hood. Put a dash of Halothane onto
a piece of gauze and place it in the chamber with the animal. Close the chamber.
Allow the animal to succumb to the anesthesia and lay still for 5 seconds.
Quickly remove the animal from the chamber and administer general anesthetic.
* The general anesthetic administered is tribromoethanol (Avertin). Use 0.025
ml/gm + 0.05 ml. Inject into the IP cavity with an insulin syringe at a 45° angle.
22.8 g = 0.62 ml 26.4 g = 0.71 ml 30.0 g = 0.80 ml
23.2 g= 0.63 ml 26.8 g= 0.72 ml 30.4 g= 0.81 ml
23.6 g = 0.64 ml 27.2 g = 0.73 ml 30.8 g = 0.82 ml
24.0 g = 0.65ml 27.4 g = 0.74ml 31.2 g = 0.83ml
24.4g=0.66ml 28.0 g=0.75ml 31.6 g = 0.84ml
24.8 g = 0.67 ml 28.4 g = 0.76 ml 32.0 g = 0.85 ml
25.2 g = 0.68 ml 28.8 g = 0.77 ml 32.4 g = 0.86 ml
25.6 g = 0.69 ml 29.2 g = 0.78 ml 32.8 g = 0.87 ml
26.0 g = 0.70 ml 29.6 g = 0.79 ml 33.2 g = 0.88 ml
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* Place the animal on hood surface. Allow the animal up to 2 minutes to become
anesthetized. Observe the animal during this period. Good anesthesia will be
effected in most animals. Some may require more. If by 2 minutes the anesthesia
is not sufficient, administer an extra 0.05 or 0.10 ml of Avertin.
* Make sure that the animal's breathing stays strong (1 breath/sec), and that the
extremities and the nose remain pink. If the animal stops breathing, gentle chest
compressions often will produce a sound rhythm. Perform anesthesia with the
second animal.
* Place the animals in the supine position. Extend the extremities. They should
move without significant resistance. The foot may be squeezed. Absence of
reflex, including respiratory spasm, indicates good anesthesia.
* The animals may now be moved to the operating area. Place them in the supine
position. The extremities are extended away from the body, and secured to the
table with tape. Check the right rear leg reflex.
* Spray the abdomens with 70% ethanol and wipe to prep surgical area.
4) Surgical procedure (laparatomy)
* Grasp the skin of the upper right quadrant of the animal with rat-tooth tweezers,
and retract gently upwards. Identify the xiphoid process and the beginning of the
pubic bone.
* An incision is made through the skin, immediately inferior to the xiphoid process
to superior to the pubic bone. Take care to minimize trauma to the abdominal
muscle.
* Use the scissors and divide the abdominal muscle along the midline from the
pubic bone to the xiphoid process.
* Make two incisions laterally from the midpoint of the abdomen down to the
operating table.
* Using a fine-nosed hemostat, grasp the free corner of one of the abdominal flaps,
lock the hemostat, and lay the hemostat on the table to retract the flap away from
the body. Repeat with the remaining 3 flaps.
* At this point, if the anesthesia appears insufficient, as evidenced by rapid
breathing or muscular movement, spray the remainder of the injection over the
viscera. If needed, use the second injection, again in doses.
5) Surgical procedure - Cannulation
* Use a sterile cotton-tipped swab to displace the intestines to the animal's left side.
* Divide ligaments connecting the large right lobe to the stomach, the small bottom
left lobe to the IVC, and the small right lobe to the stomach.
* Move the mouse under the magnifying glass for the best view.
* Cannulate the portal vein with the needle and carefully push the catheter/needle
into the vein. Remove the needle. Do the cannulation as far away from the liver
as possible so as not to push the catheter into the liver. Allow the catheter to fill
with blood.
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* With the pump on (7 ml/min), carefully measure the length/angle of tubing
needed. Tape the tubing to the incubator shelf to secure it, and insert tubing into
catheter. The liver swells and blanches. As soon as possible, cut the IVC to let
buffer out. The liver should now blanch completely. Cut the diaphragm, and the
mouse will die.
* Occlude the IVC with an applicator for - 5 seconds and allow the liver to swell
moderately. Repeat 2 more times. Continue perfusion for 15 minutes.
* Move the tube to the collagenase buffer. Wait for 1 minute. Occlude the IVC
with an applicator for - 5 seconds and allow the liver to swell. Repeat 2 more
times. Perfuse for 10 minutes.
* As the perfusion nears 8 minutes, remove the gall bladder carefully. Also, divide
the ligaments that connect the liver to the diaphragm. Be careful not to sever the
IVC.
6) Surgical procedure - Dissection
* Take out catheter and stop the pump. Note the time.
* Tilt the lobes up and grab the white fibrous connective tissue with the forceps.
Cut the portal vein connection and start pulling the liver gently away from the
mouse. Cut any ligaments that are still connected to the liver.
* Put the liver in a 100 mm Petri dish with 25 ml preservation buffer. Keep on ice.
7) Purification
* Change gloves. Use fine forceps to gash the liver sac. Agitate to get some cells
to release from liver. Scrape off cells that remain attached to the liver sac with
the cell lifter. Use as few strokes as possible to minimize cell damage.
* Filter cells through 100 pm mesh into a 50 ml tube. Wash petri dish with 20 ml
preservation buffer and filter. Pass the 45 ml through a 70 gm filter into a 50 ml
tube.
* Spin cells at 50 x g for 3 minutes (420 rpm in Cooney lab).
* Suck off media and resuspend pellet in 25 ml preservation buffer.
* Put 12.5 ml cell suspension in two 50 ml tubes and add 6 ml Percoll solution to
each.
* Spin cells at 50 x g for 5 minutes (420 rpm in Cooney lab).
* Suck off layer of dead cells and rest of Percoll solution.
* Resuspend pellets in 22.5 ml preservation buffer each, and combine the tubes.
* Spin cells at 50 x g for 3 minutes (420 rpm in Cooney lab).
* Suck off media and dissolve in 11 ml Hepatocyte Attachment Media.
* In an Eppendorf tube, add 50 gl cell suspension and 200 gl Trypan blue.
* Count cells in 5 squares. 1.5 x 106 cells/g mouse is good.
8) Cleanup
* Rinse perfusion apparatus with 10 ml 70% ethanol. Let air pass through.
* Wrap up the mouse in a black bag. Throw the applicators and gauze in biohazard
waste. Bring the mouse carcasses to the 8th floor fridge in the necropsy room.
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Wash all instruments and Pyrex bottles with water. Dry instruments.
Waterbath (41 °C)
Masterflex Pump
Silicone tubing (plat. cured)
15 ml Falcon tube
BDNeedles 16Gx 1.5"
Pyrex bottles. 250 ml
96410-13 Cole Parmer
VWR Stockroom
VWR Stockroom
VWR Stockroom
Tissue forceps, 4.5"
Dissecting scissors, 6"
Castro-Viejo scissors, 4"
Mosquito hemostats, 5"
Blunt-tipped fine forceps
Scalpel holder
Scalpel (#10)
Cell lifter
Angio catheter 24G
Halothane chamber (Tupperware)
Nylon mesh filter, 70 um
Nylon mesh filter, 100 um
Slotted incubator shelf
Insulin syringe 28Gxl"
Surgical instrument tray
Autoclave bags, 12"x 8"
Autoclave paper, 36"x36"
Cotton-tipped applicators
Gauze
Waste basin (surgery)
KCI
HEPES (free acid)
NaCl
Collagenase (Type IV)
CaCI2*2H20
D-Glucose
BSA, fract. V
Tribromoethanol
Tert Amyl Alcohol
EDTA
Percoll
25601-080
25608-316
25608-575
25607-302
25601-008
25607-925
25608-065
29442-200
21008-952
21008-950
BD-309309
62687-027
58753-194
58752-964
10806-005
P3911
S7653
C-5138
C5080
_._
A4503
90710
24048-6
E7889
P1644
VWR
VWR
VWR
VWR
VWR
VWR
VWR
VWR
MIT Surgical
VWR Stockroom
VWR
VWR
VWR
VWR
VWR
VWR
VWR
MIT Surgical
VWR Stockroom
Sigma
VWR Stockroom
Sigma
Sigma
Sigma
VWR Stockroom
Sigma
Sigma
Sigma
Sigma
Sigma
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$36.00
--.
25 ft
1
2
2
I
I
1
4
2
1
100
100
I
1
50
50
1
200
1
250
100
1000
I
500 g
1 kg
g
500 g
50g
lOg
5 ml
100 ml
100 ml
$1.91
$11.27
$52.14
$54.68
$4.44
$5.59
$26.65
$61.29
$2.03
$73.23
$73.23
$45.83
$18.42
$165.95
$73.30
$10.35
$27.95
$46.15
$198.85
$41.75
$128.00
$27.25
$27.00
$23.58
$57.20
-- 
-
-
-
I __ I I
I- - __ - - !I I ii
I ! mm
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4 HEPATOMA RESPONSE To GLUTAMINE
OSCILLATIONS
4.1 Introduction
Advances in Physiological Genomics require connecting changes in gene
sequence or gene transcription to function. A first approach to the global investigation of
these relationships is to perturb the physiology of an organism and observe time-
dependent changes in gene expression. Transcriptional profiling studies of this type have
begun to identify groups of coexpressed and interrelated genes constituting
transcriptional regulatory networks (20, 77, 181). To complement this transcriptional or
horizontal level of organization, a second vertical category of networks may be
considered that investigates responses to perturbations in physiology over time, but
includes data from the transcriptional level and the level of cell function. This second
category, which we term "physiological regulatory networks", provides a structure for
directly incorporating changes in physiology in the development of regulatory networks.
As a prototype for mammalian cell physiological regulatory networks, we have examined
the time-dependent response of confluent cultured mouse hepatoma cells to changes in
the glutamine concentration of the medium. Using this model, we report quantitative
changes in gene expression, metabolic fluxes, and metabolite levels for pathways directly
involving glutamine and its metabolites.
97
Most mammalian cells in culture require super-physiological levels of glutamine
for optimal growth. High rates of glutamine consumption are commonly observed in
tumor cell lines, hybridomas, and other rapidly proliferating cells (129). The importance
of glutamine is further demonstrated by the observation that changes in the extracellular
glutamine concentration cause metabolic shifts in mammalian cell culture (109, 121).
For example, in continuous hybridoma cultures, a step change from approximately 0 to
0.9 mM extracellular glutamine (with excess glucose present) produced a marked
increase in the consumption of glucose, glutamine, and oxygen, and the production of
ammonium, alanine, and lactate (121). This observation that glutamine is required for
high rates of glycolysis has been observed in a variety of mammalian cells. Rat
lymphocytes increased the consumption of glucose when glutamine was in the medium
(6). C6 rat glioma cells increased glucose consumption by 60% when transferred from
glutamine-free medium to 4 mM glutamine (140). When both glucose and glutamine are
available, glutamine provides a significant fraction of the cellular energy requirements,
calculated as 40% for normal diploid fibroblast cells (215) and Chinese hamster cells (46)
and as high as 70% for HeLa cells (150). This capacity for elevated glutamine
consumption may be a consequence of a distinct high capacity glutamine transport
system, which has been documented for human hepatoma cells (18). Once inside the
cell, glutamine carbon has several fates. It may enter the TCA cycle at oxaloacetate, but,
for each molecule entering the cycle, one four- or five-carbon moiety must exit to
maintain steady state. The flux of glutamine carbon to purine biosynthesis is an example
of one such biosynthetic exit path. A second pathway is exit from the TCA cycle via
malic enzyme to pyruvate, which can either be converted to lactate or acetyl-CoA. Both
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of these paths allow the cell to maintain steady state TCA cycle metabolite levels, and the
latter pathway is required for complete oxidation of glutamine. Finally, glutamine can be
converted to citrate via reductive carboxylation where isocitrate dehydrogenase carries
flux in reverse of the TCA cycle direction. This last pathway contributes significantly to
de novo lipogenesis in rat hepatoma (71) and to gluconeogenesis in normal perfused rat
liver (45).
To develop a prototype for physiological regulatory networks, we chose Hepal-6
cells, a mouse hepatoma cell line. This cell line arose from a C57/L mouse and retains
many liver-specific phenotypes, including the secretion of several serum proteins (38).
However, it does not store glycogen and has a low activity of glucose 6-phosphatase
(183), suggesting an absence of glucose production. We designed studies to
simultaneously probe the changes in metabolic function and gene expression following
removal of glutamine from the medium for 24 h followed by 24 h of 4 mM glutamine.
This glutamine depletion/repletion protocol provided the basis for investigating both
metabolic physiology and gene expression under well-controlled conditions.
4.2 Results
4.2.1 Metabolic Alterations During Glutamine Oscillations
The effect of glutamine depletion/repletion on the glycolytic flux was examined
using 3H20 release from [2-3H] and [3-3H] glucose as described in Methods (Fig. 4.1).
The glycolytic flux at time 0 was 0.30 ± 0.03 nmol/h per 104 cells and did not differ for
the two 3H tracers. This indicates that the flux through triose phosphate isomerase did
not differ from that through hexose phosphate isomerase. This agreement is expected in
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view of the high glycolytic rate in the absence of significant glucose-6-phosphatase
activity reported in Hepal-6 cells (183). Removal of glutamine from the medium led to a
gradual decline in the glycolytic rate to values approximately 50% of the control.
Restoring glutamine to the medium returned the rates to near the starting values after a
delay of approximately 12 h (Fig. 4.1), demonstrating a reversible change in flux upon
glutamine depletion and repletion.
To monitor the fate of glucose further into the oxidative pathway, 14 CO2
production from 14C-labeled glucose tracers was examined (Figs. 4.2 and 4.3). The flux
through PDH estimated with [3,4-14 C] glucose at time 0 was 0.10 + 0.01 nmol/h per 104
cells. The flux through PDH declined by 70% in the absence of glutamine. For a more
direct estimate of the effect of glutamine on TCA cycle flux, 14C0 2 production from [6-
14C] glucose was examined at 0, 24, and 48 h of the protocol (Fig. 4.3). The oxidation of
glucose estimated with [6-14C] glucose at time 0 was 0.07 + 0.01 nmol/h per 104 cells.
The TCA cycle activity measured by this indicator declined 70% during glutamine
depletion at 24 h and returned to control values by 48 h (Fig. 4.3). Taken together, these
flux indicator assays demonstrate a reversible decline in glycolytic and TCA cycle fluxes
induced by glutamine depletion and repletion.
In addition to lactate and the TCA cycle, a significant fate of glucose and
glutamine carbon is polymerization in the lipogenic pathway. The effect of glutamine
depletion/repletion on the total rate of lipogenesis was investigated by measuring the rate
of incorporation of 3H20 into lipid-soluble compounds. The lipogenic flux at time 0 was
142 + 20 pmol fatty acid/h per 106 cells. Following the trend of the other flux indicators,
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Figure 4.1. Effect of glutamine depletion/repletion
on the glycolytic flux indicator ratios. The average
experimental glycolytic flux indicator was normalized
by a 12-h averaged control glycolytic flux indicator to
yield the ratio. The hexose isomerase indicator assay
used [2-3H] glucose. The triose phosphate isomerase
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Figure 4.3. Effect of glutamine depletion/repletion
on TCA cycle flux indicator ratios. The average
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Figure 4.4. Effect of glutamine depletion/repletion
of the rate of lipogenesis determined by 3H20
incorporation. The average experimental lipogenic
flux was normalized by a 12-h averaged control
lipogenic flux to yield the ratio. The * denotes time
points where the average experimental value was
significantly different from the average control value
(n = 3, p < 0.05).
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the rate of lipogenesis fell by 80% when glutamine was removed from the medium and
slowly increased when it was replenished (Fig. 4.4). To quantify the sources of carbon
for de novo lipogenesis, ISA was employed as described in the Methods. ISA estimated
the fractional contribution of glucose and glutamine to the lipogenic acetyl-CoA pool (D)
and the fraction of newly synthesized fatty acid in esterified lipid after a 24-h incubation
(g(24 h)) (Table 4.1). In control medium, both glucose and glutamine were major
contributors to the lipogenic acetyl-CoA pool. Together, they accounted for 70% of the
lipogenic carbon. This indicates that 30% of the lipogenic carbons were either from
endogenous compounds or from compounds in the medium other than glucose and
glutamine. ISA estimated the fractional synthesis of new palmitate in 24 h as
approximately 26% of the total cellular esterified pool in control conditions. These
results contrasted with the findings in glutamine-depleted medium, where glucose
accounted for only 19% of lipogenic carbon and the fractional synthesis of new palmitate
was only 8.5% of the total. These findings indicate that glutamine depletion significantly
reduced the flux of glucose carbon into lipogenic pathways. The total esterified palmitate
for the two conditions following the 24-h tracer study was similar (Table 4.1), suggesting
that esterified palmitate turnover was greater in the presence of glutamine.
To examine whether changes in intracellular metabolites played a role in the
observed changes in glycolytic and TCA cycle rate, levels of key TCA cycle
intermediates and related amino acids were monitored during glutamine
depletion/repletion (Fig. 4.5). These data indicate that, with the exception of succinate,
which did not change over the course of treatment, the metabolite concentrations declined
rapidly when glutamine was removed from the medium, and returned to basal levels
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Table 4.1. Isotopomer spectral analysis of glucose and glutamine
utilization in palmitate synthesis
Sample Glc Gin U-'3C D g (24 h) Palmitate
Control 25mM 4mM Glc 0.37 + 0.02 0.23 0.01 10 + 1.5
Control 25 mM 4 mM Gln 0.33 + 0.01 0.28 + 0.03 10 + 1.5
Expt 25 mM 0 mM Glc 0.19 + 0.01 0.09 0.01* 8.9 ±+ 0.9
Values are means + SD. D, fractional contribution of labeled substrate to
the lipogenic acetyl-CoA pool; g (24 h), fraction of newly synthesized
fatty acid after 24-h incubation. *Difference between control and
experimental (Expt) is significant (P < 0.05). Palmitate measurements
are in terms of Pg/106 cells.
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Figure 4.5. Effect of glutamine depletion/repletion
on the metabolite pool sizes. The experimental
metabolite pool size was normalized by the control
metabolite pool size at each time point to yield the
ratio.
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when glutamine was repleted. This finding supports the anaplerotic role of glutamine
carbon in replenishing the TCA cycle and the role of glutamate transaminases in
maintaining amino acid levels. In summary, the analysis of key metabolite levels
indicated that observed changes are consistent with flux changes, and thus metabolite
changes could play a key role in altering flux in this model.
4.2.2 Role of Gene Expression in Flux Alterations
Changes in metabolic fluxes may be the consequence of changes occurring at the
transcriptional level. To evaluate the significance of new mRNA synthesis, the flux
measurements were repeated in the presence of actinomycin D (a DNA intercalator).
Cells were treated with actinomycin D for 24 h beginning either at t = 0 when glutamine
was depleted from the medium or at t = 24 h when glutamine was repleted. One-hour
flux assays were conducted at t = 24 or 48 h, following the 24-h actinomycin D exposure.
Assays measured glycolytic flux (3 H2 0 production from [2-3H] glucose), PDH flux
(14 C02 production from [3,4-14C] glucose), TCA cycle flux (14CO2 production from [6-
14C] glucose), and lipogenesis ( 3 H2 0 incorporation into lipids). Each of these assays
indicated that the observed changes in flux produced by glutamine depletion and
repletion were altered in the presence of actinomycin D. Three specific patterns are
illustrated in Figures 4.6, 4.7, and 4.8. In the presence of actinomycin D, the glycolytic
flux did not decline during glutamine depletion (Fig. 4.6A) and did not recover
completely during glutamine repletion (Fig. 4.6B). This indicates that de novo mRNA
synthesis was necessary to allow the glycolytic rate to fall when glutamine was depleted
(Fig. 4.6A) and to allow it to return to normal values when glutamine is repleted (Fig.
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Figure 4.6. Effect of actinomycin D on glycolytic flux estimated using [2-
3H] glucose over the course of glutamine depletion/repletion.
Actinomycin D was added to control and experimental groups in the first
24 h (A) or in the second 24 h (B) as indicated by a black bar. Arrow
denotes time of flux assay. In comparisons between cells in the absence
(open bars) or presence (solid bars) of actinomycin D for each glutamine
treatment (n = 6, + SD), * denotes a significant difference (p < 0.05).
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Figure 4.7. Effect of actinomycin D on TCA cycle flux estimated using [6-
14C] glucose over the course of glutamine depletion/repletion.
Actinomycin D was added to control and experimental groups in the first
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4.6B). However, the maintenance of glycolytic flux in control cells over a 24-h period
did not require de novo mRNA synthesis. The glycolytic flux indicator value at time = 0
was 0.47 + 0.04 nmol/h per 104 cells. A similar, but less pronounced pattern was seen in
the TCA cycle flux (Fig. 4.7). The TCA cycle flux indicator value at time = 0 was 0.07 +
0.01 nmol/h per 10 4 cells. A different pattern was found when the lipogenic flux was
monitored with 3H20 incorporation (Fig. 4.8). Here, de novo mRNA synthesis was
required to maintain the normal lipogenic flux over 24 h in control medium, but mRNA
synthesis was not required for decreased lipogenesis produced by glutamine depletions
(Fig. 4.8A). De novo mRNA synthesis was also required for cells to respond to
glutamine repletion (Fig. 4.8B). The lipogenic flux indicator value at time = 0 was 99.5 +
7.9 pmol FA/h per 106 cells.
4.2.3. Microarray Anatysis of Gene Expression
DNA microarray studies were conducted at specified intervals across the
glutamine depletion/repletion protocol, as described in the Methods. The gene
expression data for duplicate microarrays were merged and averaged to create a union
data set. Genes were retained in the union set only if data were available for each of the 7
time points. Analysis of this data indicated that 3,185 of the 17,280 genes were
expressed at every time point during the glutamine depletion/repletion protocol. To
capture genes with significant changes in gene expression, the data were filtered to
eliminate genes that did not have at least one time point with a log2 ratio greater than 0.6
or less than -0.6. Of the 3,185 genes, 950 genes were considered unchanged at every
time point and condition by this criterion. The remaining 2,235 genes were examined to
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determine if genes associated with the observed flux changes were altered significantly
and to determine if any of the 2,235 genes were highly correlated with the glycolytic flux
indicator or with the glutamine level in the medium. To investigate the behavior of genes
in the pathways affected by glutamine depletion/repletion, expression values for treated
cells were compared to controls at the end of glutamine depletion (24 h) and after 12 h of
glutamine repletion (36 h) (Table 4.2). Lipid synthesis increased upon glutamine
repletion and a gene catalyzing a highly regulated step in cholesterol synthesis, HMG-
CoA reductase, was found to increase upon glutamine repletion. However, fatty acid
synthase, whose expression is often found to correlate with fatty acid synthesis, was not
found to change in this study. Genes catalyzing early steps of fatty acid oxidation, acyl-
CoA synthetase and acyl-CoA dehydrogenase, increased during glutamine depletion and
decreased during the glutamine repletion. These findings are consistent with the fact that
lipid oxidation is suppressed when lipogenesis is elevated, due to the actions of malonyl-
CoA. Glycolysis increased upon glutamine repletion. Several glycolytic genes increased
upon glutamine repletion, including 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase 2, phosphofructokinase, and glucose phosphate isomerase 1 complex. It
should be noted that many metabolic genes involved in the pathways affected by
glutamine did not change significantly. Among the 950 unchanged genes were citrate
synthase, PDH-P3, pyruvate kinase, lactate dehydrogenase 1, triosephosphate isomerase,
and ATP-citrate lyase (data not shown). Acetyl-CoA carboxylase (94) and PEPCK (149)
have previously been found to be affected by glutamine oscillations, but did not qualify
for our 3,1 85-gene data set. Taken together, our results indicate that the dramatic flux
changes associated with glutamine depletion and repletion are accompanied by large
113
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Table 4.2. Expression response of genes in central carbon and lipid
metabolism to glutamine repletion.
Gene Name T = 24 h T = 36h Response
Acyl-CoA Synthetase 1.68 -0.42 Decrease
Acyl-CoA Dehydrogenase 2.08 -0.90 Decrease
Glutamate Dehydrogenase 0.69 -1.04 Decrease
Pyruvate Carboxylase 0.68 0.51 Decrease
Fatty Acid Synthase 0.36 0.12 Unchanged
6-Phosphofructo-2-kinase/Fructose2,6- 1.07 1.92 Increase
bisphosphatase 2
HMG-CoA Reductase -0.69 2.44 Increase
Phosphofructokinase -1.56 2.13 Increase
Glucose Phosphate Isomerase 1 Complex 0.08 2.31 Increase
O-actin 0.40 1.22 Increase
'T = 24 h' values reflect the log2 ratio comparing experimental and
control cells at the 24-h time point with the glutamine concentration at 0
mM. 'T = 36 h' values reflect the log2 ratio comparing experimental and
control cells at the 36-h time point, 12 h after glutamine repletion to 4
mM.
Figure 4.9. A: Gene expression profiles correlated
to hexose isomerase flux indicator with a correlation
coefficient > 0.90. B: Gene expression profiles anti-
correlated to hexose isomerase flux indicator with a
correlation coefficient < -0.90.
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Figure 4.10. Gene expression profiles anti-
correlated to autoscaled glutamine concentration
with a correlation coefficient < -0.90.
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changes in only a few of the many enzymes catalyzing the reactions in these pathways.
Finally, Table 4.2 lists the increased expression of P-actin upon glutamine repletion,
consistent with the findings of Husson et al. (75). In addition to characterizing the
behavior of genes known to be involved in the pathways affected by glutamine, we used
correlational analysis to identify genes whose expression patterns correlated with the
observed fluxes. The correlational analysis revealed a larger number of genes that were
anti-correlated with glutamine and fluxes than those that were correlated. For example,
correlational analysis of the glycolysis flux detected 9 correlated genes with a correlation
coefficient > 0.90 (Fig. 4.9A). However, 22 anti-correlated genes were detected with a
correlation coefficient < -0.90 (Fig. 4.9B). Analysis of gene expression data with the
autoscaled glutamine input signal found 16 anti-correlated genes with a correlation
coefficient less than-0.90 (Fig. 4.10). Yet, no correlated genes were found with a
correlation coefficient greater than 0.90. Finally, the gene expression data were analyzed
by a pattern discovery algorithm, Teiresias (151). The data set of log2 ratios at time
points was converted into a binary data set of positive or negative derivatives between
time points. Teiresias was then used to discover patterns within this binary data set.
Twelve genes were found to have the pattern of 3 positive derivatives followed by 3
negative derivatives (Fig. 4.11). Using the same criteria, Teiresias did not detect any
genes exhibiting the expression pattern of 3 negative derivatives followed by 3 positive
derivatives.
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Figure 4.11. Gene expression profiles discovered by
Teiresias to have a pattern of 3 positive derivatives
followed by 3 negative derivatives.
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4.3 Discussion
With the completion of the mouse genome sequence and the development of
protocols for generating transgenic animals, mouse models are providing important
insights into human diseases. The glutamine depletion/repletion protocol described here
demonstrated that changes in fluxes could be evaluated in a mouse hepatic cell model at
short time intervals over a 48-h period. This was facilitated by the development of 1-h
flux assays specifically for this project. The observed flux changes could then be
combined with data for metabolite levels and gene expression, providing a prototype for
simultaneous monitoring of fluxes, metabolite levels, and gene expression. While
previous studies with mouse hepatoma cell lines have recorded distinct enzyme
expression patterns characteristic of these cells (38), quantitative analysis of fluxes
comparable to those in human and rat hepatoma cell lines have been lacking. The present
study demonstrated that mouse Hepal-6 cells share metabolic flux characteristics with
other transformed cell lines with regard to glutamine metabolism. Consistent with
previous findings (6, 140), glutamine is required for high rates of glycolytic flux (Fig.
4.1). Glutamine is also a major source of carbon for de novo lipogenesis (Table 4.1), as
found with rat hepatoma cells (71). Thus, the Hepal-6 mouse cell line is well suited for
the investigation of physiological regulatory networks that integrate gene expression and
functional data.
The glutamine depletion/repletion protocol provided a mechanism for examining
changes in metabolic flux in terms of two key sites of controlling flux: control via
changes in the levels of substrates and other metabolites, and control via changes in the
level of mRNA mediated by transcription. Flux measurements following incubation in
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actinomycin D provided a tool for examining the necessity of transcriptional changes in
this model. The glycolytic flux response observed in response to actinomycin D
demonstrated that, in the absence of a change in glutamine, de novo mRNA synthesis was
not critical to maintaining flux (Fig. 4.6). This suggests that the mRNA and/or its protein
products required for maintenance of the glycolytic flux are relatively stable, a pattern
characteristic of a pathway that is not regulated at the transcriptional level in the short
term. The TCA cycle may also be an example of a pathway that is not transcriptionally
regulated in the short term. Citrate synthase and pyruvate dehydrogenase beta were
among the 950 genes with no significant gene expression changes during glutamine
depletion/repletion. In place of transcriptional changes, alterations in fluxes in these
pathways may be the result of control at the enzyme activity or metabolite level, a form
of regulation that allows rapid response to changing conditions. The finding that the
concentrations of five of the six metabolites correlated with the flux changes (Fig. 4.5)
provides a mechanism for changes in flux as a result of changes in substrate
concentration. Although maintenance of glycolytic flux did not require de novo mRNA
synthesis, the requirement for mRNA synthesis to effect the changes in flux during
glutamine depletion/repletion clearly indicates a role for de novo mRNA synthesis in
regulating these fluxes (Fig. 4.6). The effect of actinomycin D on the lipogenic flux
demonstrated that de novo mRNA synthesis was critical to maintaining flux. The
lipogenic mRNA and/or its protein products are less stable than glycolytic mRNA, and
may exert some control over the lipogenic flux at the transcriptional level in the short
term. Thus, in developing a more complete description of flux control in this model, the
quantitative importance both of metabolite changes and gene expression will be required.
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The use of actinomycin D in conjunction with the glutamine depletion/repletion protocol
provides a model for the analysis of the time course of transcriptional changes
modulating metabolic flux.
Changes in gene expression monitored with DNA microarrays indicated
activation of gene expression accompanied the decline in metabolic fluxes observed upon
glutamine depletion (Figs. 4.9 and 4.10). This finding brings into focus the fact that
increased transcription of some genes was required to allow cells to respond to the new
metabolic conditions created by removing glutamine from the medium. Activation of
gene expression in the absence of glutamine was also supported by the finding that
actinomycin D prevented, at least partially, the expected decline in glycolytic flux during
glutamine depletion as discussed above. Most of the genes found to be activated or anti-
correlated with glutamine levels or flux are not known to be directly connected to
intermediary metabolism. They were retained following a filter that required a
substantial change in gene expression and eliminated most genes due to either to poor
signal or small changes in expression. The Teiresias algorithm provided another method
other than correlation to identify genes of interest. Out of the 12 genes identified with the
correct 3-up/3-down pattern, 8 were also found on the list of genes from the glycolytic
flux anti-correlational analysis. In other words, 8 of the genes identified by Teiresias also
had correlation coefficients to the glycolytic flux < -0.90. The other 4 genes had
correlation coefficients between -0.71 and -0.89. Teiresias sought out genes that had a
desirable pattern, but were not necessarily highly correlated with the flux signal. While
the role of the genes detected here in modulating flux has not been resolved, the ability of
this model to examine the relationship between genes and fluxes may be an important
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tool for future studies. Another finding of note in the analysis of microarray data was
that most relevant metabolic genes did not display significant expression changes. Thus,
this study demonstrates the importance of a physiological approach combining metabolite
data and gene expression data to understand regulatory networks controlling flux. We
propose the glutamine depletion/repletion model as a prototype for developing
physiological regulatory models in integrative systems biology.
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MODULATION OF LIVER INSULIN ACTION BY
THE HEXOSAMINE BIOSYNTHETIC PATHWAY
5.1 Introduction
Development of insulin resistance is the primary pathophysiological event of
Type 2 diabetes, and many models have been developed to study the pathophysiology of
insulin resistance. Prolonged hyperglycemia is one such model and is known to induce
insulin resistance in animal and cell culture systems. In 1991, Marshall et al. discovered
that prolonged hyperglycemia enhanced flux through the hexosamine biosynthesis
pathway (HBP) and induced insulin resistance in the adipocyte glucose transport system
(111). It was postulated that under conditions of hyperglycemia, approximately to 3%
of the glucose flux through glycolysis was shunted into the HBP (111, 112). The
increased generation of hexosamine metabolites apparently enhanced the glycosylation of
proteins with N-acetylglucosamine (GlcNAc) moieties, negatively impacting insulin
signaling and yielding insulin resistance. Numerous studies in vitro and in vivo have
provided evidence supporting the involvement of the HBP in inducing insulin resistance
in adipose, muscle, and other tissue types (21, 116, 117, 132, 157, 197, 212). In
examining the HBP's mechanism of action, Patti et al. found that insulin receptor
substrate- and 2 had decreased phosphorylation in conjunction with increased
glycosylation (138). Park et al. reported that insulin receptor substrate-1 and Akt2 had
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increased glycosylation and decreased phosphorylation after treatment with PUGNAc,
which inhibits the removal of GlcNAc units from proteins (135). Spampinato et al. found
that glucosamine infusion into rats decreased insulin-stimulated insulin receptor
autophosphorylation in skeletal muscle (173). Insulin-stimulated glycogen synthase
activity in 3T3-L1 adipocytes was decreased by glycosylation (137). In total, there is
ample evidence that enhanced HBP activity interrupts insulin signaling through protein
glycosylation with HBP products, and enhanced HBP activity may be one mechanism of
hyperglycemia-induced insulin resistance. Because the liver is also an insulin-sensitive
tissue, we hypothesized that the HBP activity affected insulin sensitivity in a similar
manner in the liver.
Based on previous literature, we chose to use pharmacological agents to modulate
the HBP activity (Fig. 5.1). Alloxan, a uracil analog, was shown to inhibit O-GlcNAc
transferase in isolated pancreatic islets (91), limiting HBP activity. Glucosamine is
rapidly transported into hepatocytes through glucose transporters and undergoes direct
phosphorylation to glucosamine-6-phosphate (111, 113), increasing HBP activity.
Glucosamine bypasses the first and rate-limiting enzyme of this pathway,
glutamine:fructose-6-P amidotransferase (GFAT), circumventing the allosteric feedback
inhibition of GFAT by glucosamine-6P (24) and uridine diphosphate-N-acetyl
glucosamine (UDP-GlcNAc) (92). This allows artificially high levels of UDP-GlcNAc.
Glucosamine is also a competitor of glucose for glucokinase (11) and the glucose
transporter. Azaserine, a glutamine analog, was shown to restore insulin sensitivity to the
glucose uptake system in adipocytes (111). It was postulated that azaserine reduced HBP
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Figure 5.1. Effects of pharmacological modulators on hexosamine
biosynthetic pathway activity. Glucose and glucosamine increase HBP
activity by providing more substrate. Azaserine and alloxan decrease
HBP activity by inhibiting enzymes in the HBP.
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activity by competitively inhibiting GFAT. We used both single modulator treatments
and combination treatments to study the effect of HBP activity on insulin sensitivity.
Previous data indicated that the HBP activity might influence insulin sensitivity in
the liver. Virkamaki et al. found that infusion of glucosamine into rats abolished insulin-
and glucose-stimulated glycogen deposition by -100-fold (193). However, these data
were taken in an animal model, in which the direct effect of glucosamine infusion on the
liver was not known in detail. In the current study, we set out to test our hypotheses in
mouse hepatocytes. We focused on testing the hypotheses that 1) modulation of HBP
activity affects insulin sensitivity, and 2) enhanced HBP activity is one mechanism of
hyperglycemia-induced insulin resistance. Our experimental approach involved
modulating the HBP activity in cultured mouse hepatocytes by various pharmacological
agents and measuring the insulin-stimulated glycogen deposition and insulin suppression
of glucose production to quantify the effect on insulin sensitivity. We also investigated
the intracellular events behind these major phenotypic changes by profiling the relative
levels of various metabolites in central carbon metabolism and the HBP.
The results support the hypothesis that modulation of the HBP activity affects
insulin sensitivity, and that enhanced HBP activity is a mechanism for hyperglycemia-
induced insulin resistance. Metabolite profiling data showed that hyperglycemia
increased the pools of hexose-phosphates and hexosamine intermediates. The assumed
reduction or enhancement of HBP activity by pharmacological agents correlated with the
corresponding effect on insulin sensitivity, and was also reflected in the metabolite levels.
Taken together, we postulate that the HBP activity is one of the factors regulating insulin
sensitivity in the liver.
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5.2 Resutts
5.2.1 InsuLin-StimuLated GLycogen Synthesis
We examined first the effects of treating hepatocytes with glucosamine, azaserine,
and alloxan on insulin-stimulated glycogen deposition. The exposure of the hepatocytes
to a series of glucosamine concentrations in 5 mM glucose Preincubation medium is
shown in Fig. 5.2. The effect of glucosamine, which was to decrease insulin sensitivity
and blunt insulin-stimulated glycogen synthesis, decreased in a dose-dependent manner
and was negligible at or below 0.1 mM. The most effective concentration of glucosamine
was 1 mM, which decreased the glucose to glycogen flux by 36%. The glucosamine
treatments did not have an effect on the groups without insulin.
The effect of alloxan alone and in combination with glucosamine was examined
during treatment with 5 mM glucose Preincubation medium (Fig. 5.3). In Figure 5.3A,
treatment with 1 mM glucosamine again reduced insulin-stimulated glucose to glycogen
flux by 40%, as compared to Control. Treatment with alloxan and glucosamine reduced
insulin-stimulated glucose to glycogen flux by only 18%. The increase in insulin-
stimulated glucose to glycogen flux caused by the addition of alloxan to glucosamine was
significant, indicating that alloxan partially restored insulin stimulation of glycogen
deposition. Addition of alloxan alone to the Preincubation medium (Fig. 5.3B) did not
change the insulin-stimulated glucose to glycogen flux. The different treatments in
Figure 5.3 caused significant changes to the groups without insulin stimulation, but the
magnitudes of the changes were quite small. In both Figs. 5.3A and 5.3B, the Control
groups showed the highest insulin sensitivity, as measured by the glycogen deposition.
127
1 + Ins
o - Ins
3.0
2.5
C_O 0
o 02.0
x 1.5S 0
L .2
0 tM
8 E 1.0
0.5
0.0
Control 2 mM 1 mM 0.5mM 0.1 mM
Glucosamine (mM)
.. .. . . . .. . . . . . .. . . _ _ ... _ .. . . . . _ . . . ............................................
Figure 5.2. Insulin-stimulated glycogen deposition response to
glucosamine treatment. Cells were incubated with different doses of
glucosamine in the 5 mM glucose Preincubation medium. * = significant
difference between "+ ins" groups and their control (P < 0.05, n = 3 to 6).
Dunnett's t test was used for all comparisons.
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Figure 5.3. Insulin-stimulated glycogen deposition
response to 1 mM glucosamine and/or 3 mM alloxan
treatment. Cells were incubated with doses of
glucosamine/alloxan in the 5 mM glucose
Preincubation medium. * = significant difference
between "+ ins" groups and their control (P < 0.05, n
= 3 to 4). # = significant difference between "- ins"
groups and their control (P < 0.05, n = 3 to 4). @ =
significant different between indicated groups (P <
0.05, n = 3 to 4). Dunnett's t test was used for
comparison in panel A, while Student's t test was used
for panel B.
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Figure 5.4. Insulin-stimulated glycogen deposition
response to 1 mM glucosamine and/or 10 pM
azaserine treatment. Cells were incubated with doses
of glucosamine/azaserine in the 20 mM glucose
Preincubation medium. * = significant difference
between "+ ins" groups and their control (P < 0.05, n =
4 to 6). # = significant difference between "- ins"
groups and their control (P < 0.05, n = 4 to 6).
Dunnett's t test was used for panel A, while Student's t
test was used for panel B.
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Figure 5.5. Insulin-stimulated glycogen deposition
response to azaserine treatment. Cells were
incubated with 10 lM azaserine in the 5 mM
glucose Preincubation medium. * = significant
difference between "+ ins" groups and their control
(P < 0.05, n = 4 to 5). # = significant difference
between "- ins" groups and their control (P < 0.05,
n = 4). Student's t test was used.
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Next, we examined the effect of glucosamine and azaserine at high concentrations
of glucose (20 mM) in the Preincubation medium (Fig. 5.4). Addition of glucosamine
(Fig. 5.4A) reduced insulin-stimulated glucose to glycogen flux by 11% from Control,
which was much less than the reduction in the 5 mM glucose Preincubation case.
Addition of glucosamine and azaserine reduced the insulin-stimulated glucose to
glycogen flux further (25% from Control). These effects were contrasted with
preincubation with azaserine (Fig. 5.4B), which led to a 30% increase in insulin-
stimulated glucose to glycogen flux over Control.
Azaserine was tested for its effect in the presence of 5 mM glucose Preincubation
medium (Fig. 5.5). There was a significant decrease in insulin sensitivity in the
azaserine-treated cells, but the change was small (10%). This result was in contrast to
azaserine's effect in the 20 mM glucose Preincubation treatment.
5.2.2 Insulin Suppression of Glucose Production
We next explored the effect of the different modulators on glucose production
under insulin suppression and glucagon stimulation. The effect of glucosamine and/or
alloxan with 5 mM glucose Preincubation medium was examined first (Fig. 5.6). Panel
A shows the results with lactate/pyruvate in the Assay medium. The addition of
glucosamine had significant effects on both the insulin treatment (24% increase in
glucose production) and the glucagon treatment (22% decrease in glucose production).
These effects showed glucosamine-induced resistance to both insulin and glucagon.
Alloxan by itself had little effect on insulin sensitivity, but adding alloxan to glucosamine
improved insulin sensitivity and nearly reduced glucose production back to Control level.
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Figure 5.6. Glucose production response to 1 mM
glucosamine and/or 3 mM alloxan treatment. Cells
were incubated with doses of glucosamine/alloxan in
the 5 mM glucose Preincubation medium. A: Assay
medium with lactate/pyruvate. B: Assay medium with
lactate/pyruvate and glycerol.
* = significant difference between "Ins" groups and
their control (P < 0.05, n = 3 to 5). # = significant
difference between "Ggn" groups and their control (P <
0.05, n = 3 to 5). ( = significant difference between
indicated groups (P < 0.05, n = 3 to 5). Dunnett's t test
was used for all comparisons. Ggn = glucagon.
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Figure 5.7. Glucose production response to 1 mM
glucosamine and/or 10 jiM azaserine treatment.
Cells were incubated with glucosamine/azaserine in
the 20 mM glucose Preincubation medium. A:
Assay medium with lactate/pyruvate. B: Assay
medium with lactate/pyruvate and glycerol.
* = significant difference between "Ins" groups and
their control (P < 0.05, n = 3 to 4). Dunnett's t test
was used for all comparisons.
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The glucose production experiments were repeated with 1.5 mM glycerol as an
additional gluconeogenic substrate in the Assay medium (Fig. 5.6B). The Control group
displayed very similar glucose production to the Control group in panel 5.6A despite the
addition of glycerol. When 1 mM glucosamine was added to the Preincubation medium,
glucose production in the presence of insulin was increased by 29% and glucose
production in the presence of glucagon was decreased by 25%, as compared to Control.
Again, the cells had decreased insulin and glucagon sensitivity. Addition of 3 mM
alloxan did not have a significant effect on insulin suppression of glucose production.
But when added with glucosamine, alloxan suppressed glucose production by 42% when
compared with Control and 55% when compared with the GlucN treatment. These
results with glycerol in the Assay medium were very similar to the results without
glycerol, indicating that glycerol did not have a significant impact on the metabolism.
Next, the effect of glucosamine and/or azaserine was tested in the presence of 20
mM glucose Preincubation medium (Fig. 5.7). Panel A shows the results from adding
lactate/pyruvate to the Assay medium. In contrast to 5 mM glucose Preincubation
medium, the Control group in 20 mM glucose Preincubation medium had the highest
glucose production, therefore was the least sensitive to insulin. Hyperglycemia had
reduced insulin sensitivity, mirroring the results in glycogen deposition. There was no
change in glucose production when 1 mM glucosamine was added. The addition of
azaserine, on the other hand, increased the sensitivity of the cells to insulin, and glucose
production was suppressed by 56% compared to the Control group with insulin. When
both azaserine and glucosamine were added to the hepatocytes, the insulin suppression
was not as effective. The addition of glucosamine increased glucose production by 62%
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as compared to the treatment of azaserine alone. All treatments seemed to have no effect
on the glucagon sensitivity.
The effect of glucosamine and/or azaserine was tested in the presence of 20 mM
glucose Preincubation medium (Fig. 5.7B) with glycerol added to the Assay medium.
Hyperglycemia reduced insulin sensitivity, and addition of 1 mM glucosamine to the
Preincubation medium left the insulin suppression of glucose production unchanged. The
addition of azaserine increased the sensitivity of the cells to insulin, and glucose
production was suppressed by 47% when compared to the Control group with insulin.
Addition of glucosamine and azaserine did not significantly change glucose production as
compared to azaserine alone, but glucose production was still significantly below the
Control level. These results largely agreed with the results obtained without glycerol in
the Assay medium (Fig. 5.7A).
5.2.3 Metabolite Level Quantification
We further explored the intracellular effects of the different treatments by
quantifying the relative changes in metabolite levels in response to the changes in glucose
level and the addition of pharmacological agents. In all experiments, metabolite levels in
a particular treatment were normalized to that same metabolite's level in a reference
treatment (1 mM glucose Preincubation medium with no modulators), as mentioned in
Materials and Methods. As such, all metabolites for the reference treatment would have
relative metabolite levels of 1.0.
We first examined the hepatocytes with 5 mM glucose Preincubation medium
(Table 5.1). The Control treatment showed that 5 mM glucose caused a mild buildup of
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glycolytic and HBP intermediates in comparison to the reference state. GlucN treatment
further increased glucose-6P levels, and drastically boosted all four HBP intermediates.
Alloxan treatment made significant increases to upper glycolytic intermediates glucose-
6P, fructose-6P, and PEP. However, it only increased the upper three HBP intermediates,
and left the UDP-GlucNAc- 1 P pool unchanged. The combination of glucosamine and
alloxan in the GlucN/Allox group produced an synergistic effect. Glucose-6P and
fructose-6P were increased beyond what either single modulator had achieved. All four
HBP intermediates were also increased in a synergistic fashion, ranging from 2x to 6x
the amount in the Control group. In all four treatments, the TCA cycle intermediate
levels were not perturbed from the reference state.
We then profiled the metabolites in several treatments with 20 mM glucose in the
Preincubation medium (Table 5.2). In the Control group, the levels of glucose-6P,
fructose-6P, and UDP-glucose-lP were higher than they were with 5 mM glucose. The
upper three HBP intermediates were also increased over the 5 mM glucose treatment.
When glucosamine was added to 20 mM glucose, the UDP-GlucNAc-1P pool was
increased by almost 4x, and the citrate pool was decreased by nearly 40%. The addition
of azaserine only increased the GlucNAc-6P pool over the Control group. The
GlucN/Aza treatment resulted in a mild increase of GlucNAc and a 7x increase of UDP-
GlucNAc- 1 P.
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Table 5.1. Metabolite levels after treatment with 5 mM glucose
Preincubation medium.
Pathway Control GlucN Alloxan GlucN/Allox
Glycolysis
G6P 3.7 0.5 4.9 ±+ 0.8 8.1 + 1.1 12.6 +1.6
F6P 1.6 ±+ 0.1 1.7 +± 0.4 2.5 + 0.3 3.7 + 0.4
PEP 2.1 ± 0.4 2.1 ± 0.6 2.9 ±+ 0.6 2.9 + 0.3
PYR 1.2 + 0.2 0.9 +± 0.1 1.0 +± 0.2 0.8 + 0.1
UDP-Gluc-lP 0.9 ± 0.1 0.8 + 0.1 0.9 ± 0.2 1.0 +0.2
HBP
GlucN6P 3.3 + 0.3 4.8 +± 0.5 8.0 ±+ 0.9 12.0 + 1.2
GlucNAc6P 2.2 ±+ 0.5 3.6 + 0.6 3.7 ±+ 0.4 4.5 + 0.6
GlucNAc 2.3 ±+ 0.3 3.3 + 0.2 4.0 ±+ 0.5 4.9 + 0.5
UDP-GlucNAc-IP 1.1 ±+ 0.2 4.9 + 0.7 1.4 ±+ 0.2 6.5 + 0.5
TCA Cycle
Citrate 1.2 ±+ 0.2 0.8 + 0.2 1.4 + 0.2 1.2 + 0.2
a-KG 1.1 +± 0.1 1.0 + 0.1 1.2 ±+ 0.1 1.1 + 0.1
Succinate 0.9 0.1 0.9 0.1 0.7 0.1 0.8 + 0.1
Fumarate 1.0 + 0.1 0.8 + 0.1 1.0 ±+ 0.1 0.9 + 0.1
Malate 1.1 0.1 0.9 0.1 1.1 0.1 0.9 +0.0
Values are means + SD of n = 3 to 5 replicates. The values represent the
ratio of the pool size of a particular metabolite in the indicated treatment with
the pool size of the same metabolite in a reference treatment of 1 mM glucose
and no modulators. Control, treatment with no modulators; GlucN, treatment
with 1 mM glucosamine; Alloxan, treatment with 3 mM alloxan; Both,
treatment with 1 mM glucosamine and 3 mM alloxan; UDP-Gluc-IP,
combined pools of glucose-lP and UDP-glucose; UDP-GlucNAc-1P,
combined pools of glucNAc- 1P and UDP-glucNAc. All groups have 5 mM
glucose.
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Table 5.2. Metabolite levels after treatment with 20 mM glucose
Preincubation medium.
Pathway Control GlucN Azaserine GlucN/Aza
Glycolysis
G6P 7.6 ± 0.4 6.6 ± 0.7 7.2 ± 0.8 6.8 ± 0.7
F6P 7.1 + 0.7 6.8 + 0.6 7.3 + 0.3 6.5 + 0.6
PEP 1.3 0.3 1.1 0.2 1.8 0.4 1.7 0.3
PYR 1.4 0.2 1.2 0.2 1.6 0.1 1.4 0.2
UDP-Gluc-IP 1.9 + 0.2 1.4 + 0.2 2.5 + 0.3 2.3 + 0.3
HBP
GlucN6P 8.4 0.9 8.1 0.5 8.4 0.8 7.8 0.7
GlucNAc6P 5.3 + 0.2 4.0 ± 0.2 7.7 + 0.6 5.5 + 0.4
GlucNAc 3.8 ± 0.3 4.0 ± 0.4 4.2 ± 0.3 5.3 ± 0.2
UDP-GlucNAc-lP 1.2 ± 0.2 4.4 ± 0.3 1.6 ± 0.2 8.5 ± 0.4
TCA Cycle
Citrate 1.6 0.3 1.0 0.1 1.7 0.1 1.4 0.2
x-KG 0.6 0.1 0.6 0.1 0.6 0.1 0.6 0.1
Succinate 0.9 0.1 0.8 0.0 1.0 0.1 1.0 0.1
Fumarate 1.3 + 0.2 1.0 + 0.0 1.4 + 0.2 1.1 + 0.1
Malate 1.4 0.1 1.0 0.1 1.5 0.1 1.2 0.1
Values are means + SD of n = 3 to 5 replicates. The values represent the
ratio of the pool size of a particular metabolite in the indicated treatment
with the pool size of the same metabolite in a reference treatment of 1 mM
glucose and no modulators. Control, treatment with no modulators; GlucN,
treatment with 1 mM glucosamine; Azaserine, treatment with 10 p.M
azaserine; Both, treatment with 1 mM glucosamine and 10 gM azaserine;
UDP-Gluc- P, combined pools of glucose- P and UDP-glucose; UDP-
GlucNAc- P, combined pools of glucNAc- P and UDP-glucNAc. All
groups have 20 mM glucose.
139
5.3 Discussion
Hyperglycemia is a main characteristic of Type 2 diabetes mellitus that stems
from insulin resistance. It also contributes to disease pathogenesis by impairing both
insulin sensitivity and insulin secretion (85, 95, 170, 209). Thus, hyperglycemia is not
only a symptom of diabetes, but also a driving force that can sustain or worsen the
diabetic state. A strong hypothesis for a cellular mechanism of hyperglycemia is its
effect on the HBP. The elevated glucose concentration shunts carbon flux towards the
HBP, increasing the generation of hexosamine intermediates. The latter, in turn, increase
protein glycosylation and ultimately deactivate insulin signaling proteins (among other
proteins), which induces further insulin resistance.
In the liver tissue, insulin action has the dual role of inducing glycogen synthesis
and suppressing glucose production. The glycogen synthesis assay was only concerned
with the activation of glycogen synthase by insulin (43, 97, 98). Insulin and glucagon
affect glucose production by regulating several important enzymes in hepatic glucose
production, which is the sum of glycogenolysis and gluconeogenesis. Insulin activates
glycogen synthesis and glycolysis, while glucagon activates glycogenolysis and
gluconeogenesis. Insulin activates glycogen synthase (43, 97, 98), glucokinase (79), and
pyruvate kinase (17). Insulin antagonizes the activation of glycogen phosphorylase (78),
PEPCK (12), G6Pase (12), pyruvate carboxylase (80). Glucagon exerts a repressive
effect on glucokinase (79), pyruvate kinase (17), and glycogen synthase (51). Glucagon
activates glycogen phosphorylase (78) and the key gluconeogenic enzymes PEPCK,
G6Pase (12), and pyruvate carboxylase (80). Given the evidence that enhanced HBP
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activity impairs insulin signaling (135, 138, 173), it follows that modulation of HBP
activity may influence insulin regulation of glycogen deposition and glucose production.
5.3.1 Correlation of HBP Activity and Insulin Sensitivity
Previous investigators have used glucosamine to artificially increase HBP activity
(10, 113-115, 137, 138, 154, 193). These experiments have shown that addition of
glucosamine to cells or infusion of glucosamine into animals blunts the insulin-stimulated
glucose uptake of muscle and adipose tissue. Our experiments showed that glucosamine
decreased insulin sensitivity in mouse hepatocytes under the low glucose Preincubation
treatment. Insulin stimulation of glycogen deposition and insulin suppression of glucose
production were diminished by glucosamine. This suggested that the HBP activity in the
low glucose Preincubation treatment was minimal and the addition of glucosamine
increased it substantially, resulting in reduced insulin sensitivity. In contrast, the addition
of glucosamine to high glucose Preincubation treatments had little effect on insulin
sensitivity in terms of glucose production and glycogen deposition. So unlike the low
glucose treatments, the HBP activity in the high glucose state was assumed to be near
saturation, and glucosamine increased HBP activity only incrementally. Insulin
sensitivity was therefore expected to be unchanged, and these data were consistent with
the negative correlation between HBP activity and insulin sensitivity.
Regarding the inhibitory effect of glucosamine on glucose transport and
phosphorylation, we examined the effect of glucosamine on the treatments without
insulin. Glucosamine is phosphorylated to glucosamine-6-phosphate by glucokinase, and
is therefore a competitive inhibitor of glucokinase with respect to glucose (11). This
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inhibition of glucokinase and the use of the GLUT2 glucose transporter by glucosamine
were possible contributors to insulin resistance outside of HBP effects. However, the
glucosamine treatments were much less effective at reducing glycogen deposition without
the presence of insulin. In the glucose production experiments, glucosamine had either
no effect or decreased glucose production in the presence of glucagon, instead of
increasing the glucose production as it did in the presence of insulin. These results
indicate that the effects of glucosamine outside of the HBP were negligible in our system.
The combination treatment of glucosamine with alloxan also provides key evidence that
the insulin desensitizing effect of glucosamine was mainly due to increasing HBP
activity. The treatment of the hepatocytes with alloxan alone did not affect insulin
sensitivity at low or high Preincubation glucose (data not shown for alloxan treatments
with high glucose incubation) for glycogen deposition or glucose production, making the
case against alloxan affecting glucokinase activity or GLUT2 capacity by itself.
However, when alloxan and glucosamine were added in combination at low glucose,
alloxan improved insulin sensitivity in comparison to glucosamine alone, suggesting that
alloxan stemmed the increase in HBP activity from glucosamine. Previous investigators
have shown that alloxan was able to abolish the increase in glycosylation caused by
glucosamine (91). Since it is unlikely that alloxan affected glucokinase activity or
GLUT2 capacity, these data support the hypothesis that alloxan and glucosamine exerted
an effect on insulin sensitivity by modulating HBP activity, and by extension, protein
glycosylation. It is interesting to note that alloxan did not increase insulin sensitivity at
high glucose Preincubation. One possible explanation is that glucose also generated
aminosugars other than GlucNAc that affected insulin sensitivity, and alloxan was only
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able to inhibit the O-GlcNAc transferase. The situation with alloxan is to be contrasted
with azaserine, which was able to restore insulin sensitivity by inhibiting HBP activity
further up in the pathway. Precluding glucose carbon from even entering the hexosamine
metabolism seemed to be more effective than merely preventing O-GlcNAc transfer.
From the behavior of these two inhibitors, it is plausible that aminosugars other than
glucosamines, such as mannosamines and galactosamines, may also play a role in insulin
sensitivity.
Azaserine has been used previously to increase the insulin sensitivity of glucose
transport in primary adipocytes (111). Azaserine was theorized to increase insulin
sensitivity by decreasing HBP activity through GFAT inhibition. Our data showed that
azaserine had little effect on insulin action in the low glucose Preincubation treatment,
and had a large positive effect in high glucose Preincubation treatment for both glycogen
synthesis and glucose production. It was expected that azaserine would have a minimal,
or perhaps detrimental, effect at low glucose because the activity of the HBP would be
relatively small. The presence of high glucose provided a large carbon flux into the HBP
that would distinguish between the presence and absence of azaserine. We saw that
azaserine enhanced insulin sensitivity in glucose production as compared to the Control
treatment, suggesting that hyperglycemia reduced insulin sensitivity through enhanced
HBP activity. The combination of glucosamine with azaserine neutralized the increase in
action provided by azaserine alone, both for glycogen deposition and glucose production.
We hypothesize that glucosamine increased HBP activity in the presence of azaserine by
entering the HBP downstream of GFAT (azaserine's inhibition target). Taken together,
the data suggest that azaserine increased insulin sensitivity by decreasing HBP activity.
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In total, the glycogen deposition and glucose production data suggest that the HBP
activity correlated negatively with insulin sensitivity, and that the HBP was one
mechanism by which prolonged hyperglycemia caused insulin resistance.
5.3.2 Modulator Mechanisms by Metabotite Profiling
We used metabolite profiling (53) to gain insight into the intracellular effects of
increasing glucose from 5 mM to 20 mM and adding pharmacological agents to the
medium. Raising the glucose level from 5 mM to 20 mM predictably raised hexose
phosphates and most of the HBP intermediates, and yet, lower glycolytic intermediates
such as phosphoenolpyruvate (PEP) and pyruvate were unchanged. These results are
consistent with the hypothesis that excess fructose-6P was shunted into the HBP.
Addition of glucosamine to the 5 mM glucose Preincubation treatment increased
all intermediates in the HBP, whereas the effect was much smaller in the 20 mM glucose
Preincubation treatment. This is consistent with the previous result that glucosamine had
a detrimental effect on insulin sensitivity at low glucose, but no effect at high glucose.
We hypothesize that the activity of the HBP was enhanced by glucosamine at 5 mM
glucose, whereas the HBP activity was already near its maximum at 20 mM glucose.
Another interesting point was the differing levels of the UDP-GlcNAc/GlcNAc-lP pool
between the high glucose treatments with and without glucosamine. It is known that
GFAT is feedback inhibited by glucosamine-6P (24) and UDP-GlcNAc (60), and the
addition of glucosamine seemed to bypass this inhibition. However, due to the
measurement of the combined pool, we cannot say for certain this is the case. The
addition of glucosamine to 5 mM glucose Preincubation medium did not decrease the
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levels of glycolytic intermediates, indicating that inhibition of glucokinase may not have
been significant.
The results of the alloxan treatment were consistent with the previously reported
inhibition of O-GlcNAc transferase (91). HBP intermediates were greatly increased, and
the effect extended to the hexose phosphates. Given their modes of action, it was not
surprising to see that glucosamine and alloxan had synergistic effects on hexose
phosphate and HBP intermediate levels. These results were consistent with the
hypothesis that alloxan countered glucosamine's effects on insulin sensitivity by
decreasing flow of HBP intermediates to protein glycosylation, corresponding to
alloxan's restorative action in the insulin sensitivity experiments.
The inhibition of GFAT by azaserine was not apparent from the metabolite
profiling data. It was expected that azaserine would decrease the concentration of HBP
intermediates, but azaserine seemed to actually increase GlcNAc-6P. Since azaserine is a
glutamine analog, it was possible that it could inhibit entry of glutamine into the TCA
cycle. Our metabolite profiling data showed that the levels of ac-ketoglutarate and other
TCA cycle intermediates did not change with the addition of azaserine, suggesting that
azaserine did not have an impact on the TCA cycle.
We were concerned with possible "side effects" of the metabolite level changes
brought on by alloxan and glucosamine in the 5 mM Preincubation medium. Alloxan and
glucosamine induced large changes in metabolite pools, which could have had some
unintended effects on glycogen synthesis and glucose production. The dramatic increases
in the G6P metabolite pool were of particular concern because G6P is an important
substrate for the ensuing glycogen deposition and glucose production assays. However,
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we noted that there was no effect on glycogen deposition in the absence of insulin when
glucosamine was added. Addition of alloxan did not increase glycogen deposition or
glucose production in the presence of insulin despite the doubling of G6P. Finally,
addition of glucosamine and alloxan together cancelled out glucosamine's effects for
glycogen deposition and glucose production. The sensitivity phenotypes of the
hepatocytes in glycogen deposition and glucose production were the same with no
modulators as with both modulators present even though the metabolite profiles were
wildly different. It is possible that the washing step and the change to the Assay medium
eliminated any differences in intracellular metabolite levels. These observations led us to
conclude that the pharmacological side effects did not play a major role in insulin
sensitivity.
5.3.3 Conclusions
Elucidation of the pathophysiology of Type 2 diabetes and the etiology of
hyperglycemia-mediated diabetic complications is essential to the development of
potential treatment strategies. We presented evidence that the HBP activity is negatively
correlated with liver insulin sensitivity, and that the HBP is a mechanism for
hyperglycemia-induced insulin resistance in primary hepatocytes. To our knowledge,
these are the only data showing the effect of HBP activity on hepatocytes and on glucose
production. Consequently, we now have evidence that the HBP plays a key role in
sensing hyperglycemic conditions in all 3 peripheral insulin targets: liver, muscle, and
adipose tissue. We postulate that this pathway, under chronic hyperglycemia, triggers a
cascade of responses that lead to impaired insulin signaling and insulin resistance. The
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data here and in previous HBP literature underline the increasingly important role of the
HBP in regulating insulin sensitivity and energy homeostasis. A dysfunctional HBP may
contribute to the pathophysiology of Type 2 diabetes.
Further studies are needed to confirm the role of the HBP in hepatic insulin
resistance. In addition to the phenotypic and metabolite profiling data provided here,
more detailed studies of the molecular actions of the HBP, similar to ones in muscle and
adipose tissue, are needed. It is imperative that the assumed events between
manipulation of HBP activity and the affected glycogen deposition or glucose production
are consistent with our hypothesis that the HBP is modulating insulin sensitivity. That is,
the glycosylation and phosphorylation states of insulin signaling proteins should correlate
with the metabolic data, as should activity or transcription of metabolic enzymes in the
glycogenesis or gluconeogenesis pathways.
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BlOREACTION NETWORPK ANALYSIS OF HEPATIC
GLUCOSE PPODUCTION
6.1 Introduction
Hyperglycemia is both a common feature of Type 2 diabetes and a known inducer
of insulin resistance in animal and cell culture models (111). Whole body studies in
humans using the glucose clamp suggest that increased hepatic glucose production (HGP)
is a major contributor to the hyperglycemia observed in Type 2 diabetes (122, 182).
Despite differences in etiology in animal models of Type 2 diabetes (genetic, diet, or
surgical), abnormalities in the control of HGP appear to be a common feature. With
regard to the source of the excess HGP, there is evidence that increased gluconeogenesis
is responsible for the elevated HGP observed in Type 2 diabetes (32). To better
understand the factors regulating HGP, we examined the response of the HGP bioreaction
network in cultured mouse hepatocytes to a set of systematic perturbations in order to
gain insight into the physiology underlying the control of HGP.
We used an array of perturbations to gather a diverse set of data that represented
many different glucose production phenotypes, as well as many configurations of the
glucose production network. One set of perturbations was the use of insulin and
glucagon to treat the hepatocytes. As shown in Fig. 2.4, insulin and glucagon affect
glucose production by regulating several important enzymes in hepatic glucose
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production, which is the sum of glycogenolysis and gluconeogenesis. Insulin activates
glycogen synthesis and glycolysis, while glucagon activates glycogenolysis and
gluconeogenesis (12, 17, 43, 51, 78-80, 97, 98).
Another perturbation was the preincubation of hepatocytes in hyperglycemic
conditions. Prolonged hyperglycemia is known to induce insulin resistance in animal and
cell culture systems (111 I), apparently through the increased generation of hexosamine
metabolites and subsequent glycosylation of proteins with N-acetylglucosamine
(GlcNAc) (135, 137, 138, 173). It was postulated that under conditions of
hyperglycemia, approximately 1 to 3% of the glucose flux through glycolysis was
shunted into the hexosamine biosynthetic pathway (HBP) (111, 112). In addition to
hyperglycemia, we also chose to use pharmacological agents to modulate HBP activity.
Alloxan (91) and azaserine (111) were used to limit HBP activity. Glucosamine (111,
113) was used to increase HBP activity. Thus, hyperglycemia and HBP activity seem to
be connected and both seem to affect insulin sensitivity.
The final type of perturbation varied the gluconeogenic substrate availability with
the presence and absence of glycerol in the Assay medium. The presence of glycerol
gave the cells a gluconeogenic substrate that was unaffected by PEPCK activity, which
became important in elucidating the control structure of the glucose production network.
The results revealed some of the principles determining the glucose production
phenotype and the configuration of the bioreaction network. Hyperglycemia led to a
greater contribution of glycogenolysis to glucose production, and the composition of the
gluconeogenic flux was dependent on the available substrates. Perturbations in
hyperglycemia, hormones, and HBP activity affected overall glucose production.
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Gluconeogenesis was much larger than glycogenolysis, and therefore regulation of
gluconeogenesis determined the glucose production phenotype. The prominence of
gluconeogenesis agreed with results found in Type 2 diabetes patients and other animal
models. G6Pase was identified as the enzyme in gluconeogenesis controlling the glucose
production phenotype, whereas PEPCK played a secondary role.
6.2 Results
6.2.1 Relative Intracellular Flux Measurements
We estimated some of the intracellular fluxes that contributed to glucose
production under different treatments. The glucose production data already showed that
the absolute amount of glucose produced varied with different treatments, and
subsequently we examined the changes in the central carbon flux map (Fig. 6.1) during
the different treatments. Flux 1 represents the flux from glycogenolysis to G6P. Flux 2
represents the flux from gluconeogenesis to G6P. Flux 3 represents the flux from
glycerol to gluconeogenesis. Flux 4 represents the net flux from DHAP to GAP, and flux
5 represents the flux from amino acids, lactate, and pyruvate to gluconeogenesis.
First, we labeled the Assay medium with 10% D20, leaving all other pre-assay
conditions identical to those of the original glucose production experiments. These
labeling experiments probed the glucose production results shown in Figs. 5.6A and
5.7A. As mentioned in the Methods, the isotopic labeling information allowed Metran to
estimate fluxes 1, 2, 4, and 5 (Tables 6.1 and 6.2). Since there was no glycerol in the
Assay medium, the lower gluconeogenic flux provided all of the gluconeogenic carbon.
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Figure 6.1. Metabolic network for glucose production flux calculations.
1, flux from glycogenolysis; 2, flux from gluconeogenesis; 3,
gluconeogenic flux from glycerol to DHAP; 4, net flux from DHAP to
GAP; 5, gluconeogenic flux from lactate, pyruvate, and amino acids.
152
Glucose
1
G6P - Glycogen
2
Glycerol 3 DHAP GAP
t5
Lactate
Pyruvate
Amino Acids
L
Table 6.1. Relative glycogenolysis and gluconeogenesis fluxes assayed
with D2 0 labeling.
Glucose Level Modulator Hormone Glycogenolysis Gluconeogenesis
Low Glucose Control Ins 6.9 + 1.3 93.1 + 1.3
Ggn 9.0 + 1.3 91.0 + 1.3
GlucN Ins 10.5 + 1.3 89.5 + 1.3
Ggn 10.1 ±+ 1.3 89.9 ±+ 1.3
Allox Ins 10.4 + 1.3 89.6 1.3
Ggn 9.2 + 1.3 90.8 + 1.3
Both Ins 10.3 + 1.3 89.7 + 1.3
Ggn 11.7 + 1.3 88.3 + 1.3
High Glucose Control Ins 24.0 + 0.7 76.0 + 0.7
Ggn 23.5 + 0.6 76.5 + 0.6
GlucN Ins 23.9 + 0.6 76.1 + 0.6
Ggn 25.1 ±+ 0.6 74.9 + 0.6
Aza Ins 29.5 ± 0.6 70.5 ± 0.6
Ggn 27.3 + 0.6 72.7 + 0.6
Both Ins 28.5 + 0.6 71.5 ± 0.6
Ggn 22.8 + 1.1 77.2 1.1
Values are the optimal fluxes calculated by Metran to fit glucose
isotopomer data, + SD. The values represent the contribution of
glycogenolysis (Flux 1) and gluconeogenesis (Flux 2) to glucose
production (normalized to 100). Control, treatment with no modulators;
GlucN, treatment with 1 mM glucosamine; Aza, treatment with 10 gM
azaserine; Allox, treatment with 3 mM alloxan; Both, treatment with both
modulators used in glucose group.
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Table 6.2. Relative fluxes contributing to gluconeogenesis assayed
with D20 labeling
Glucose Level Mod Hormone Low to GAP DHAP to GAP
Low Glucose Control Ins 186.2 + 2.7 -93.1 + 1.3
Ggn 182.0 + 2.7 -91.0 + 1.3
GlucN Ins 179.0 + 2.6 -89.5 + 1.3
Ggn 179.8 + 2.7 -89.9 + 1.3
Allox Ins 179.2 + 2.7 -89.6 + 1.3
Ggn 181.6 + 2.7 -90.8 + 1.3
Both Ins 179.4 + 2.7 -89.7 + 1.3
Ggn 176.6 + 2.7 -88.3 + 1.3
High Glucose Control Ins 152.0 + 1.4 -76.0 + 0.7
Ggn 153.0 + 1.3 -76.5 + 0.6
GlucN Ins 152.2 + 1.3 -76.1 + 0.7
Ggn 149.8 + 1.3 -74.9 + 0.6
Aza Ins 141.0 + 1.3 -70.5 + 0.6
Ggn 145.4 + 1.3 -72.7 ±+ 0.6
Both Ins 143.0 +± 1.3 -71.5 + 0.6
Ggn 154.4 ±+ 2.7 -77.2 ±+ 1.4
Values are the optimal fluxes calculated by Metran to fit glucose
isotopomer data, + SD. The values represent the contribution of net
DHAP GAP (Flux 4) lower gluconeogenesis (Flux 5) to the
gluconeogenesis (Flux 2) values shown in Table 6.1. Low to GAP =
flux of lactate, pyruvate, and amino acids to GAP; DHAP to GAP =
net flux from DHAP to GAP; Control, treatment with no modulators;
GlucN, treatment with 1 mM glucosamine; Aza, treatment with 10
[tM azaserine; Both, treatment with both modulators used in specific
glucose group.
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Table 6.3. Relative glycogenolysis and gluconeogenesis fluxes assayed
with [U-13C] glycerol labeling
Glucose Level Modulator Hormone Glycogenolysis Gluconeogenesis
Low Glucose Control Ins 10.4 + 0.4 89.6 + 0.4
Ggn 11.2 + 0.4 88.8 + 0.4
GlucN Ins 11.7 ±+ 0.4 88.3 + 0.4
Ggn 10.9 + 0.5 89.1 + 0.5
Allox Ins 11.4 + 0.4 88.6 + 0.4
Ggn 9.8 + 0.4 90.2 + 0.4
Both Ins 10.0 + 0.3 90.0 + 0.3
Ggn 10.7 + 0.4 89.3 + 0.4
High Glucose Control Ins 18.3 ± 0.3 81.7 + 0.3
Ggn 17.9 +0.5 82.1 ± 0.5
GlucN Ins 18.4 + 0.4 81.6 + 0.4
Ggn 17.4 ± 0.5 82.6 ± 0.5
Aza Ins 16.1 + 0.4 83.9 0.4
Ggn 20.6 + 0.5 79.4 ± 0.5
Both Ins 18.1 + 0.4 81.9 + 0.4
Ggn 18.2 0.4 81.8 0.4
Values are the optimal fluxes calculated by Metran to fit glucose
isotopomer data, + SD. The values represent the contribution of
glycogenolysis (Flux 1) and gluconeogenesis (Flux 2) to glucose
production (normalized to 100). Control, treatment with no modulators;
GlucN, treatment with 1 mM glucosamine; Aza, treatment with 10 p.M
azaserine; Allox, treatment with 3 mM alloxan; Both, treatment with both
modulators used in specific glucose group.
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Table 6.4. Relative fluxes contributing to gluconeogenesis assayed with [U-13C]
glycerol labeling
Glucose Level Mod Horm Glyc to DHAP Low to GAP DHAP to GAP
Low Glucose Control Ins 91.2 ±+ 0.2 87.9 + 0.9 1.6 + 0.5
Ggn 86.7 ±+0.2 90.9 ±+0.8 -2.1 +0.5
GlucN Ins 93.3 ± 0.2 83.3 ± 0.8 5.0 + 0.5
Ggn 87.6 +± 0.2 90.6 ±+ 1.0 -1.5 + 0.5
Allox Ins 92.5 + 0.2 84.7 + 0.9 3.9 + 0.5
Ggn 88.1 ±+ 0.2 92.3 ±+ 0.8 -2.1 + 0.5
Both Ins 93.4 ±+ 0.2 86.6 + 0.7 3.4 + 0.4
Ggn 86.9 ± 0.2 91.7 ± 0.8 -2.4 +0.5
High Glucose Control Ins 84.4 + 0.2 79.0 ±+ 0.7 2.7 ± 0.4
Ggn 78.3 + 0.2 85.9 ±+ 1.0 -3.8 + 0.6
GlucN Ins 85.6 ± 0.2 77.6 ± 0.8 4.0 + 0.5
Ggn 81.8 + 0.2 83.4 ±+ 1.0 -0.8 +0.5
Aza Ins 87.8 ± 0.2 80.0 ± 0.8 3.9 +0.5
Ggn 79.3 ±+ 0.2 79.5 + 0.9 -0.1 + 0.5
Both Ins 87.6 ± 0.2 76.2 ± 0.8 5.7 +0.4
Ggn 82.6 ±+ 0.2 81.1 + 0.9 0.8 + 0.5
Values are the optimal fluxes calculated by Metran to fit glucose isotopomer data,
+ SD. The values represent the contributions of glycerol (Flux 3), net DHAP 
GAP flux (Flux 4), and lower gluconeogenesis (Flux 5) to the gluconeogenesis
values (Flux 2) shown in Table 6.3. Glyc to DHAP = flux of glycerol to DHAP;
Low to GAP = flux of lactate, pyruvate, and amino acids to GAP; DHAP to GAP =
net flux from DHAP to GAP; Control, treatment with no modulators; GlucN,
treatment with 1 mM glucosamine; Aza, treatment with 10 PiM azaserine; Both,
treatment with both modulators used in specific glucose group.
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Thus, its flux was not independent and was always double the gluconeogenic flux. The
carbon from lower gluconeogenesis was split evenly between DHAP and GAP.
In another experiment, we added 1.5 mM [U-'3C] glycerol as the labeled substrate
to the Assay medium. With the addition of glycerol, the assay conditions now
corresponded to the glucose production results shown in Figs. 5.6B and 5.7B. This
labeling strategy allowed the estimation of fluxes 1, 2, 3, 4, and 5 (Tables 6.3 and 6.4).
As outlined in the Methods, these relative intracellular flux maps were the basis for
calculating the absolute flux maps.
6.2.2 Absolute Intracellttutar Flux Measurements
The absolute fluxes for the D20 labeling scheme are shown in Tables 6.5 and 6.6,
and those for [U-13C] glycerol labeling scheme are shown in Tables 6.7 and 6.8.
Examination of the overall glucose production rates revealed that addition of glycerol to
the Assay medium did not change the results significantly. However, changing the
Preincubation glucose level had a large effect. Focusing on the Control groups, it was
observed that high glucose Preincubation treatment reduced the glucose production
significantly in the glucagon-treated Controls, but not insulin-treated Controls. The
reduction in the glucagon-treated Control illustrated the suppression of glucose
production by hyperglycemia per se. When azaserine was added, insulin suppression of
glucose production was restored, and it was apparent that the high glucose Control group
was insulin resistant. The glucose production in the insulin-treated high glucose Control
group was significantly lower than that in the insulin-treated Control group with low
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Table 6.5. Absolute glycogenolysis and gluconeogenesis fluxes assayed with D20
labeling.
Glucose Level Mod Horm Glycogenolysis Gluconeogenesis Total
Low Glucose Control Ins 13.8 + 2.7 187.5 + 4.6 201.3 + 4.0#
Ggn 29.5 ±+4.5 296.6 11.8 326.1 + 12.1
GlucN Ins 25.5 + 3.5 216.1 + 11.3 241.6 + 12.1
Ggn 26.8 + 3.8 239.0 + 13.2 265.7 + 14.1
Allox Ins 19.9 + 2.6 171.3 + 6.0 191.2 + 6.0
Ggn 27.5 + 4.1 272.4 + 10.0 299.9 + 10.1
Both Ins 21.7 + 2.9 189.6 + 4.6 211.4 + 4.0
Ggn 35.2 + 4.2 264.7 + 9.7 299.9 + 10.1
High Glucose Control Ins 44.1 + 2.9 139.3 + 8.5 183.4 + 11.0
Ggn 52.1 ±+ 8.3 169.8 ± 26.7 221.9 ± 34.8*
GlucN Ins 48.3 ±+ 2.6 153.5 + 7.1 201.7 + 9.2
Ggn 56.5 +± 9.8 169.0 + 28.9 225.6 + 38.5
Aza lns 24.9 ±+ 2.8 59.5 + 6.5 84.4 + 9.2
Ggn 55.5 + 7.6 148.1 + 20.0 203.6 + 27.5
Both Ins 44.4 +± 6.9 111.5 + 17.1 155.9 + 23.8
Ggn 46.5 +± 6.3 157.1 ± 19.9 203.6 + 25.7
Values are the means + SD (nmol/l0 6 cells). Control, treatment with no modulators;
GlucN, treatment with 1 mM glucosamine; Aza, treatment with 10 !iM azaserine;
Allox, treatment with 3 mM alloxan; Both, treatment with both modulators used in
glucose group.
* denotes a significant difference when compared to Low Glucose-Control-Ggn
treatment. P < 0.05.
# denotes a significant difference when compared to High Glucose-Aza-Ins
treatment. P <0.05.
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Table 6.6. Absolute fluxes contributing to gluconeogenesis assayed with
D20 labeling
Glucose Level Modulator Hormone Low to GAP DHAP to GAP
Low Glucose Control Ins 374.8 + 9.2 -187.4 + 4.6
Ggn 593.5 + 23.6 -296.8 + 11.8
GlucN Ins 432.4 + 22.5 -216.2 + 11.3
Ggn 477.8 + 26.3 -239.0 + 13.2
Allox Ins 342.6 + 12.0 -171.3 + 6.0
Ggn 544.7 + 19.9 -272.5 + 10.0
Both Ins 379.2 + 9.2 -189.7 + 4.6
Ggn 529.7 + 19.5 -264.8 + 9.7
High Glucose Control Ins 278.8 + 16.9 -139.4 + 8.5
Ggn 339.5 + 53.4 -169.8 + 26.7
GlucN Ins 307.0 + 14.2 -153.5 + 7.1
Ggn 337.9 + 57.8 -169.0 + 28.9
Aza Ins 119.0 + 13.0 -59.5 + 6.5
Ggn 296.0 + 40.1 -148.0 + 20.0
Both Ins 222.9 + 34.2 -111.5 + 17.1
Ggn 314.3 + 40.0 -157.2 + 20.0
Values are the means + SD (nmol/106 cells). Low to GAP = flux of
lactate, pyruvate, and amino acids to GAP; DHAP to GAP = net flux
from DHAP to GAP; Control, treatment with no modulators; GlucN,
treatment with 1 mM glucosamine; Aza, treatment with 10 M
azaserine; Both, treatment with both modulators used in specific glucose
group.
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Table 6.7. Absolute glycogenolysis and gluconeogenesis fluxes assayed with [U-
'
3C] glycerol labeling
Glucose Level Mod Horm Glycogenolysis Gluconeogenesis Total
Low Glucose Control Ins 21.3 + 2.9 182.7 + 23.8 204.0 + 26.5#
Ggn 37.1 + 3.7 293.3 + 27.2 330.5 + 30.6
GlucN Ins 29.8 + 1.1 225.2 + 2.1 255.0 + 2.0
Ggn 28.5 + 2.2 232.6 + 14.6 261.1 + 16.3
Allox Ins 20.5 ± 6.6 159.0 + 50.6 179.5 + 57.1
Ggn 29.2 + 1.8 268.7 + 12.9 297.8 + 14.3
Both Ins 11.8 + 2.1 106.5 + 18.4 118.3 + 20.4
Ggn 21.6 + 2.1 180.4 + 16.4 202.0 + 18.4
High Glucose Control Ins 35.2 + 3.6 156.7 + 15.7 191.9 + 19.2
Ggn 35.3 + 3.6 162.3 + 15.8 197.7 + 19.2*
GlucN Ins 30.4 3.3 134.6+ 14.1 165.0+ 17.3
Ggn 26.0 ±+ 4.1 123.7 + 19.0 149.7 + 23.0
Aza Ins 16.3 + 5.3 85.4 27.4 101.7 + 32.6
Ggn 41.5 + 5.6 160.0 + 21.4 201.5 + 26.9
Both Ins 21.2 + 1.5 95.8 + 6.3 117.1 + 7.7
Ggn 27.2 + 4.2 122.4 + 18.8 149.7 + 23.0
Values are the means ± SD (nmol/106 cells). Control, treatment with no
modulators; GlucN, treatment with 1 mM glucosamine; Aza, treatment with 10 gM
azaserine; Allox, treatment with 3 mM alloxan; Both, treatment with both
modulators used in glucose group.
* denotes a significant difference when compared to Low Glucose-Control-Ggn
treatment. P < 0.05.
# denotes a significant difference when compared to High Glucose-Aza-Ins
treatment. P < 0.05.
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Table 6.8. Absolute fluxes contributing to gluconeogenesis assayed with [U-13 C]
glycerol labeling
Glucose Level Modulator Horm Glyc to DHAP Low to GAP DHAP to GAP
Low Glucose Control Ins 186.1 ±+ 24.2 179.3 + 23.4 3.3 + 1.1
Ggn 286.5 + 26.5 300.4 + 28.0 -6.9 + 1.7
GlucN Ins 237.9 + 2.0 212.4 + 2.7 12.7 + 1.2
Ggn 228.7 + 14.3 236.5 + 15.0 -3.9 + 1.4
Allox Ins 166.1 +52.8 152.1 +48.4 6.9 +2.4
Ggn 262.5 + 12.6 274.9 + 13.4 -6.2 + 1.4
Both Ins 110.5 + 19.0 102.5 + 17.7 4.0 + 0.8
Ggn 175.4 + 16.0 185.3 + 16.9 -4.8 + 1.1
High Glucose Control Ins 162.0 + 16.2 151.6 + 15.2 5.2 + 1.0
Ggn 154.8 + 15.0 169.8 + 16.6 -7.5 + 1.3
GlucN Ins 141.3 + 14.8 128.1 + 13.5 6.7 + 1.0
Ggn 122.5 + 18.8 124.9 + 19.3 -1.2 + 0.8
Aza Ins 89.3 + 28.6 81.4 + 26.1 4.0 + 1.4
Ggn 159.8 + 21.3 160.2 + 21.4 -0.2 + 1.0
Both Ins 102.5 + 6.7 89.2 + 5.9 6.6 + 0.7
Ggn 123.6 + 19.0 121.3 + 18.7 1.1 + 0.8
Values are the means i SD (nmol/106 cells). Glyc to DHAP = flux of glycerol to
DHAP; Low to GAP = flux of lactate, pyruvate, and amino acids to GAP; DHAP to
GAP = net flux from DHAP to GAP; Control, treatment with no modulators;
GlucN, treatment with 1 mM glucosamine; Aza, treatment with 10 ,tM azaserine;
Allox, treatment with 3 mM alloxan; Both, treatment with both modulators used in
glucose group.
161
glucose preincubation, which again illustrated the suppression of glucose production by
hyperglycemia per se.
We also observed that gluconeogenesis was a significantly larger flux than
glycogenolysis in all treatments. Changes in the gluconeogenic flux largely, positive or
negative, determined the glucose production phenotype, a result that was confirmed in the
correlational analysis.
6.2.3 Corretationat Anatysis
The patterns in the data generated by the intracellular flux analysis were further
analyzed by examining the possible correlations between each of the intracellular fluxes
and the overall glucose production. Additionally, we created judicious data subsets and
regressed each subset with the glucose production to search for a significant improvement
in the correlations, as described in Methods. All parameters for the correlational analysis
are listed in Table 6.9.
Figures 6.2 and 6.3 show the correlation of the glycogenolysis flux with glucose
production with the data points as a single set (6.2) and after splitting the data set into
Preincubation medium treatments with low and high glucose (6.3). Analysis of the
residuals validated the two-group approach. It was apparent that the Preincubation
glucose level indeed impacted the way glycogenolysis was used in glucose production.
Splitting the glycogenolysis data according to other perturbations did not yield significant
improvement in the residuals. We observed that the best-fit line for the low glucose data
had a higher slope than the high glucose, which was reflective of the lower contribution
of glycogenolysis to glucose production in the low glucose incubations. The difference
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Table 6.9. Parameters for the best-fit lines in the correlational
analysis.
Flux Division Slope Intercept SSall SStotal
Fluxes as single data sets
1 -- 2.15 0.18 171.03 + 5.08 935.7 1307.6
2 -- 1.04 0.03 19.67 6.61 28.8 1307.6
3 -- 1.00+ 0.05 19.14+ 10.62 7.1 1085.6
4 -- 0.06 + 0.01 232.56 + 1.77 1053.4 1289.2
5 -- 0.11 0.01 196.95 3.82 993.2 1289.2
Fluxes split into 2 sets SSsubgroup SStotal
1 HighGlucose 3.46 0.33 35.17+ 11.73 32.7 171.6
Low Glucose 4.48 + 0.24 124.97 ± 6.44 123.6 464.4
2 HighGlucose 1.26+0.11 3.41 13.12 3.4 171.6
Low Glucose 1.18 0.06 -12.64+ 11.95 6.4 464.4
4 No Glycerol -0.98 + 0.05 26.6 + 8.79 23.2 507.0
Glycerol 6.47 + 0.81 207.11 + 4.71 396.3 1085.6
5 No Glycerol 0.49 - 0.02 26.63 + 8.79 23.0 507.0
Glycerol 1.10 +0.05 20.68 + 10.56 7.9 1085.6
Fluxes are numbered as in Fig. 6.1. "Division" indicates how the data
set was split. "High Glucose" denotes 20 mM glucose Preincubation
treatment. "Low Glucose" denotes 5 mM glucose Preincubation
treatment. "No Glycerol" denotes no glycerol in the Assay medium.
"Glycerol" denotes 1.5 mM glycerol in the Assay medium.
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Figure 6.2. Correlation of glycogenolysis flux to glucose
production with a single regression. Data points included
were all 32 glycogenolysis and glucose production flux
measurements from the D2 0 and [U-13C] glycerol labeling
schemes.
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Figure 6.3. Correlation of glycogenolysis flux to glucose
production after regressing low and high glucose Preincubation
treatments separately. Data points included were all 32
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in the y-intercepts was also reflective of the larger contribution of glycogenolysis glucose
production in the high glucose Preincubation treatment. We hypothesized that the
relationship between glycogenolysis and glucose production varied with the amount of
glycogen stored, assuming that high glucose preincubation resulted in a larger glycogen
store. After the high glucose Preincubation treatment, the hepatocytes apparently utilized
glycogen in a more aggressive manner to produce glucose.
Figures 6.4 and 6.5 show the correlation of the gluconeogenesis flux with glucose
production as a single data set (6.4) and after splitting the data set into Preincubation
medium treatments with low and high glucose (6.5). Analysis of the residuals validated
the two-group approach, although the improvement was not as large as in the
glycogenolysis case. We again concluded that the Preincubation glucose level impacted
the way gluconeogenesis was used in glucose production, but not to the extent as in
glycogenolysis. Splitting the gluconeogenesis data according to other perturbations did
not yield significant improvement in the residuals. In both regressions, the slopes of the
best-fit lines were near 1.0 and the y-intercepts were near 0, reflecting the dominating
contribution of gluconeogenesis to glucose production. The large contribution of
gluconeogenesis combined with the higher R2 coefficients for gluconeogenesis suggested
that gluconeogenesis contributed to glucose production in a more profound, perhaps even
more controlling manner relative to glycogenolysis under all perturbations - hormones,
Preincubation glucose level, glycerol availability, and HBP activity.
Next, we correlated the glycerol uptake to glucose production (Fig. 6.6). The data
points included here were the 16 conditions from the [U-13C] glycerol labeling
experiment. Glycerol uptake correlated very well with glucose production and, by
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Figure 6.4. Correlation of gluconeogenesis flux to glucose
production with a single regression. Data points included
were all 32 gluconeogenesis and glucose production flux
measurements from both D20 and [U-13C] glycerol
labeling schemes.
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Figure 6.5. Correlation of gluconeogenesis flux to glucose
production after regressing low and high glucose Preincubation
treatments separately. Data points included were all 32
gluconeogenesis and glucose production flux measurements
from the D20 and [U-13C] glycerol labeling schemes.
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measurements from the [U-13C] glycerol labeling scheme.
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association, total gluconeogenesis. The slope of the best-fit line was -1, which
corresponded to glycerol contributing half the 3-carbon units going towards
gluconeogenesis.
Figures 6.7 and 6.8 show the correlation of the net DHAP GAP flux to glucose
production as a single data set (6.7) and after splitting the data set into Assay medium
incubations with and without glycerol (6.8). Analysis of the residuals showed that the
two-group regression was appropriate, and the net DHAP GAP flux behavior
depended on the availability of gluconeogenic substrates. The net DHAP GAP flux
was dependent on the gluconeogenic flux in the no glycerol case, and so it was expected
to be well correlated to glucose production. The case with glycerol showed a weak
correlation with glucose production, as well as a small magnitude.
Figures 6.9 and 6.10 show the correlation of the lower gluconeogenic flux to
glucose production in a single data set (6.9) and after splitting the data set into Assay
medium incubations with and without glycerol (6.10). Analysis of the residuals validated
the two-group approach. Splitting the lower gluconeogenesis data according to other
perturbations did not yield significant improvement in the residuals. We observed that
the availability of glycerol changed the manner in which lower gluconeogenesis was used
to supply 3-carbon units for gluconeogenesis. In the case without glycerol, the slope of
the best-fit line was - 0.5 because lower gluconeogenesis provided all of the 3-carbon
units for glucose production. With glycerol, the slope of the best-fit line was - 1 because
lower gluconeogenesis only provided half of the 3-carbon units for glucose production.
This behavior of the lower gluconeogenesis pathway indicated that its utilization for
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Figure 6.7. Correlation of net DHAP GAP flux to
glucose production with a single regression. Data points
included were all 32 net DHAP GAP and glucose
production flux measurements from the D20 and [U-13C]
glycerol labeling schemes.
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Figure 6.8. Correlation of net DHAP - GAP flux to glucose
production after regressing Assay medium incubations with and
without glycerol separately. Data points included were all 32 net
DHAP - GAP and glucose production flux measurements from
the D2 0 and [U-13C] glycerol labeling schemes. The inset graph
shows data from the [U-13C] glycerol labeling on a more
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Figure 6.9. Correlation of lower gluconeogenesis flux to
glucose production with a single regression. Data points
included were all 32 lower gluconeogenesis and glucose
production flux measurements from the D20 and [U-13C]
glycerol labeling schemes.
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Figure 6.10. Correlation of lower gluconeogenesis flux to
glucose production after regressing Assay medium
incubations with and without glycerol separately. Data
points included were all 32 lower gluconeogenesis and
glucose production flux measurements from the D20 and
[U-13C] glycerol labeling schemes.
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glucose production was dependent on the availability of gluconeogenic substrates. The
presence of glycerol greatly reduced the use of lactate, which was the largest initial
extracellular substrate pool in lower gluconeogenesis.
6.3 Discussion
6.3.1 Control of Glucose Production Network
We combined the glucose production data, absolute flux maps, and correlational
analysis to gain insight into the structure of the glucose production network and the
control of the glucose production phenotype. We found that perturbations in the
Preincubation glucose level led to changes in the configuration of the G6P node and in
the overall glucose production. First, the Preincubation glucose level defined the
interaction of glycogenolysis and gluconeogenesis at the G6P node, as shown in the
correlational analysis. In both interaction regimes, the gluconeogenic flux was the
dominant factor in determining glucose production. Second, the Preincubation glucose
level also affected overall glucose production in a two-fold manner. High glucose
Preincubation treatment blunted glucose production in the glucagon-treated Control
groups. This inhibition of glucose production by hyperglycemia per se was in agreement
with previous literature (1, 16, 52, 58, 162, 168, 169, 172). Hyperglycemic preincubation
also induced insulin resistance, which was corrected by addition of azaserine. The
dominant role of gluconeogenesis during these phenotypic changes suggested that the
regulation and dysregulation of HGP was dependent on gluconeogenesis.
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Changes in glycerol availability had effects that were limited to the
reconfiguration of the pathways contributing to gluconeogenesis. Besides the obvious
changes to glycerol uptake and net DHAP GAP flux, the availability of glycerol also
revealed the flexibility of the lower gluconeogenesis branch. Without glycerol, lower
gluconeogenesis carried a very high flux (exactly double that of overall gluconeogenesis),
which we assumed to originate largely from lactate/pyruvate. With glycerol in the Assay
medium, that flux was approximately halved, and yet the total gluconeogenic flux and
overall glucose production stayed approximately the same. Since all other conditions
were identical, it was likely that there was excess lower gluconeogenic capacity when
glycerol was available. Therefore, within a given gluconeogenic substrate environment,
the lower gluconeogenesis flux was very well correlated with glucose production. But
across different substrate availabilities, the lower gluconeogenesis flux changed
drastically without affecting the glucose production phenotype. It was clear from this
behavior that the fluxes from glycerol and lower gluconeogenesis were coordinated to
fulfill the demand for gluconeogenic substrates to produce G6P. We think it would be
interesting to test if other gluconeogenic substrates such as alanine, aspartate, and acetate
act with a similar coordination.
In contrast to the perturbations of Preincubation glucose level and Assay medium
glycerol, the different treatments of hormones and HBP activity modulation modified the
overall glucose production without reconfiguring the network. The intracellular fluxes
moved in concert along the best-fit line that related them to glucose production. In
general, glucagon increased glucose production, and insulin decreased it. Two-group
regressions split according to hormone treatment were not statistically accepted. This
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result indicates that hormone treatments acted through similar mechanisms, which is
consistent with the knowledge that glucagon and insulin affect the same enzymes in
glucose production. Modulation of glucose production through HBP activity may have
come about by modifying hormone action (25).
On the basis of these observations, we hypothesize the control structure of the
glucose production network to be as follows. G6Pase consumption of G6P sets the
demand for G6P production. Depending on the glycogen store size, glycogenolysis and
gluconeogenesis fulfilled the G6P production in a coordinated manner, with higher
glycogen content (i.e., high glucose preincubation) increasing the contribution of
glycogenolysis. Gluconeogenesis was always a much larger flux and less random, and so
the regulation or dysregulation of gluconeogenesis dominated the glucose production
phenotype. The pathways supplying 3-carbon units for gluconeogenesis were then
coordinated according to the availability of gluconeogenic substrates. In this hierarchy,
we concluded that the driving force that determined the glucose production phenotype
was the G6Pase activity. PEPCK activity was normally secondary in hierarchy, but
gained importance when there was no glycerol available and lactate/pyruvate was the
only significant gluconeogenic substrate in the Assay medium. It is our hypothesis, then,
that G6Pase activity determined the glucose production phenotype, and that dysregulation
of G6Pase can lead to insulin resistant phenotypes.
The association of G6Pase and PEPCK dysregulation with Type 2 diabetes is
consistent with our conclusion about the importance of gluconeogenesis in insulin
resistant glucose production phenotypes. Normally, gluconeogenesis is responsible for
the sustained production of glucose in fasting animals (86, 96), but it is inappropriately
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active in the diabetic state. In the liver, dysfunctional regulation of PEPCK and G6Pase
gene promoters was associated with the pathophysiology of Type 2 diabetes (13, 156,
184, 187). In individuals with Type 2 diabetes, altered rates of gluconeogenesis were
responsible for increased hepatic glucose production and the observed chronic
hyperglycemia (31, 32, 41, 105). In diabetic rats, Rossetti et al. found a marked increase
in hepatic glucose production (-2-fold), glucose cycling (2.7-fold), and gluconeogenesis
(2.7-fold), while the rate of hepatic glycogenolysis was similar to that in control animals.
Furthermore, the increment in hepatic glucose production above control levels could be
accounted for entirely by the marked increase in gluconeogenic flux (158). Our
hypothesis regarding the dominant role of G6Pase in gluconeogenesis may add to our
understanding of the dysregulation of HGP in Type 2 diabetes.
6.3.2 Conclusions
Elucidation of the pathophysiology of Type 2 diabetes and the etiology of
hyperglycemia-mediated diabetic complications is paramount in the development of a
treatment strategy. With that goal in mind, our study examined the structure of the
glucose production network in hepatocytes. Through intracellular flux maps and
correlational analysis, we found that the dysregulation of gluconeogenesis was mainly
responsible for the insulin resistance seen in hepatocytes under prolonged hyperglycemia.
Perturbations in hormones and HBP activity affected overall glucose production, while
perturbations in glycerol availability affected the configuration of the glucose production
network. Perturbations in the glucose preincubation level affected both. Taking all the
data into account, we concluded that G6Pase was the most important enzyme in
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determining the glucose production phenotype. Although PEPCK was also an important
enzyme in gluconeogenesis, its importance was secondary to G6Pase in the control
hierarchy, except when lower gluconeogenesis provided all the gluconeogenic carbon.
We think it would be very useful in future studies to assay the mRNA expression
of G6Pase under insulin regulation after perturbing the system with Preincubation
glucose level, hormones, and HBP activity. Further efforts must also be put forth to
characterize the regulation of this complex, multifunctional enzyme by insulin and
glucagon, with the goal of understanding its possible dysregulation in Type 2 diabetes.
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) CONCLUSIONS ANP D RECOMMENDATIONS
7.1 ConcLusions
It was demonstrated in this thesis that the integration of gene expression data and
different types of metabolic data can provide valuable insight into the physiology of a
cellular system. The overall phenotype characterization provided by radioisotope-
incorporation/release flux measurements or biochemical assays give the researcher a
simple, coarse-grain picture of the metabolism to evaluate the overall response of the
system. Correlation with gene expression data can suggest interesting candidates for the
drivers of that response at the expression level. Then, metabolite profiling and stable
isotope flux calculations can be done to explore the details behind the overall phenotype
and increase the understanding of the phenomena leading to the cellular response. If
these calculations can be detailed enough to be evaluated in the background of previous
biological knowledge about the regulation of metabolism, then the integration of
knowledge makes the conclusions that can be drawn much more valuable.
The method presented in this thesis for functional genomics is an alternative to
what has been published previously in the field. The use of a metabolic flux pattern for
correlation to gene expression profiles provided a more specific functional endpoint for
the coregulated gene clusters in question. The use of the pattern discovery tool Teiresias
was also shown. This body of work is in need of validation to confirm the actual function
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of the gene clusters that were found. The more expedient method may be to take the
genes that were anticorrelated with the glycolytic flux, and suppress them by RNAi.
Then the cells could be assayed to confirm that expression of these genes was necessary
for the reduction of the glycolytic flux.
This thesis also presented data showing the HBP as a causal mechanism for
hyperglycemia-induced insulin resistance. The activity of the HBP was negatively
correlated with liver insulin sensitivity. These data agree with literature showing HBP-
induced insulin resistance in muscle and adipose tissue, completing the analysis of the
major peripheral insulin-sensitive tissues. These studies make it increasingly likely that
HBP is a major player in the exacerbation of the insulin resistant state in Type 2 diabetes,
as well as a primary factor in the development of insulin resistance.
Finally, the analysis of the glucose production bioreaction network revealed
several features of the network. The intracellular flux data and correlational analysis
presented revealed that dysregulation of gluconeogenesis was responsible for the loss of
insulin sensitivity in glucose production. It was also found that the gluconeogenic
enzyme G6Pase was ultimately responsible for the glucose production phenotype. Thus,
the regulation of G6Pase and gluconeogenesis are of utmost concern in controlling
hepatic glucose overproduction in Type 2 diabetes.
7.2 Recommendations
In this context, I propose that future work in the area of HBP research concentrate
on these goals:
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* Identification of molecular events in hyperglycemia-induced insulin
resistance in hepatocytes
* Identification of targets of HBP regulation
* Characterization of effects of HBP activity on G6Pase/PEPCK mRNA
expression
* Correlation of HBP activity and insulin resistance in humans
* Identification of polymorphisms in HBP enzymes associated with insulin
resistance in humans.
The first three points suggest research that will be done in animals or cells, and the last
two points will be researched in humans. These thrusts will define the scope of HBP
regulation of energy homeostasis and define the impact of the HBP on human insulin
resistance and Type 2 diabetes.
As mentioned in Chapter 5, the metabolic effects described provide the impetus
for molecular studies. The progression of research in muscle and adipose tissue advanced
in the same fashion: metabolic studies to identify the gross effect of hyperglycemia, and
then molecular studies to flesh out the events in between. The hepatocyte studies are
starting later, but will likely follow the same trajectory as the other tissues. The timeline
will probably be shorter, as the hepatocyte studies will be guided by the preceding studies
in the other two tissues.
The work on the identification of the targets of HBP regulation is progressing
steadily. The regulation of targets by the HBP is carried out by reversible glycosylation
by O-GlcNAc residues on target proteins. This regulation is akin to the mechanism of
phosphorylation. As mentioned in Chapter 5, several insulin signaling intermediates
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have been shown to be regulated by O-GlcNAc glycosylation. It has been demonstrated
that glycosylation of insulin signaling proteins inhibited their phosphorylation. This
presents a very strong model for the HBP disruption of glucose uptake in muscle and
adipose, glycogen synthesis in muscle and liver, and suppression of glucose production in
liver. However, it is known that O-GlcNAc glycosylation affects many other pathways.
Beyond insulin signaling, increased HBP flux was shown to increase leptin production in
3T3-L1 adipocytes through transcriptional mechanisms (213). Gronning et al. showed
that hyperglycemia increased the levels of transcription repressor Id2 through the HBP
(61). Id2 is a protein that indirectly regulates gene expression by sequestering certain
transcription factors and preventing them from forming functional dimers. Id2 targets
include the class-A bHLH transcription factors and the sterol regulatory element binding
protein 1 (SREBP- 1). Id2 blocked the SREBP1 induced induction of hormone sensitive
lipase promoter activity. Rumberger et al. showed that increased HBP flux upregulated
mRNA transcription of fatty acid synthase, acetyl-CoA carboxylase, and glycerol-3-
phosphate dehydrogenase (161). Such regulation may connect the HBP with the Type 2
diabetes characteristic of dyslipidemia. These results show that the domain of HBP
regulation goes far beyond glucose metabolism. The HBP truly has a role in overall
energy homeostasis.
The next logical step after identifying HBP glycosylation targets is to check the
on expression of target genes. In the case of insulin signaling proteins, the targets are
known. Concentrating on glucose production, the main targets are G6Pase and PEPCK.
Insulin signaling should normally repress the expression of these genes, and an increase
in HBP flux should release the repression. To our knowledge, no group has examined
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these gene expression effects. In studies in muscle and adipose tissue, the phenotypic
measurement of insulin sensitivity was GLUT4 translocation for glucose uptake, which
did not involve gene expression mechanisms. In this study, it seems clear that gene
expression plays a role, due to the known transcriptional mechanisms of G6Pase and
PEPCK regulation by insulin.
There are very few clinical studies examining the role of the HBP in human
insulin resistance. Two studies using glucosamine infusions found no effects on glucose
utilization during a euglycemic insulin clamp or on hepatic glucose production. Humans
may be less sensitive to the insulin resistance-promoting effect of GlucN than rodents
(125, 142). In two other studies, the hypothesis of a simple positive correlation between
hexosamine intermediate levels in muscle or adipose tissue and insulin resistance was not
supported (143, 144). However, I think the variables studied here were ambiguous. The
levels of hexosamine intermediates provide no information about the flux going through
the pathway to protein glycosylation. It is the protein glycosylation that is associated
with insulin resistance. With more informative human studies, we will find out if the
human results correspond to the results from animals and cells.
The hyperglycemia and the activity of the HBP represent the effects of the
nutritional environment, and the other side of the equation is the genetic makeup of the
individual. The introduction mentioned the polymorphisms studied so far that have been
associated with insulin resistance and Type 2 diabetes. Since there is such a mountain of
evidence regarding HBP's role as a secondary factor in exacerbating the insulin resistant
state, I would not be surprised if polymorphisms in HBP enzymes turned out to be
primary defects associated with insulin resistance. Indeed, some genetic studies have
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uncovered polymorphisms connecting the HBP and insulin resistance. Four hundred and
twelve Caucasian nondiabetic, metabolically characterized individuals were screened for
expression of two single-nucleotide polymorphisms in the 5'-flanking region of GFAT.
One of them (-913 G/A) was associated with a significantly higher body mass index,
percent body fat, and increased intramyocellular lipid content in males but no in females
(196). A recent publication reports that a single-nucleotide polymorphism in intron 10 of
the gene expressing O-GlcNAcase is associated with Type 2 diabetes in Mexican
Americans (99). Intron 10 contains an alternate stop codon and may lead to decreased
expression of the 130-kDa isoforms, which is predicted to contain the O-GlcNAcase
activity. The gene is located on chromosome 10 Oq and overlaps a region that has been
previously shown to be associated with Type 2 diabetes.
As the field of hexosamine biosynthetic pathway research matures, I think it will
make a significant contribution to the understanding of insulin resistance
pathophysiology. Although the role of the HBP in human insulin resistance is currently
undetermined, the strong evidence in animals and the preliminary evidence in humans
make it seem likely that a role for the HBP in the development of insulin resistance and
Type 2 diabetes will prevail. The management of Type 2 diabetes may indeed involve
therapies that attempt to decrease the activity of the HBP by inhibiting one of more of its
key enzymes. Understanding the HBP's connection with insulin signaling, leptin
signaling, and other energy homeostasis-related endocrinology will be important in
understanding the pathogenesis of Type 2 diabetes and slowing it down.
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